

UCLA

UCLA Previously Published Works

Title

Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms

Permalink

<https://escholarship.org/uc/item/5d291070>

Authors

Geng, Meng
Lin, Andrew
Nguyen, Thao P

Publication Date

2020

DOI

10.3389/fphar.2020.581837

Peer reviewed



Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms

Meng Geng[†], Andrew Lin and Thao P. Nguyen^{*}

Division of Cardiology, Department of Medicine, The Cardiovascular Research Laboratory, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States

OPEN ACCESS

Edited by:

Chrishan S. Samuel,
Monash University, Australia

Reviewed by:

Tamer M. A. Mohamed,
University of Louisville, United States
Ursula Ravens,
Technische Universität Dresden,
Germany

*Correspondence:

Thao P. Nguyen
tpnguyen@mednet.ucla.edu

†Present address:

Saint Mary's Hospital,
Waterbury, CT, United States

Specialty section:

This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 09 July 2020

Accepted: 17 September 2020

Published: 09 November 2020

Citation:

Geng M, Lin A and Nguyen TP (2020)
Revisiting Antiarrhythmic Drug Therapy
for Atrial Fibrillation: Reviewing
Lessons Learned and Redefining
Therapeutic Paradigms.
Front. Pharmacol. 11:581837.
doi: 10.3389/fphar.2020.581837

Since the clinical use of digitalis as the first pharmacological therapy for atrial fibrillation (AF) 235 years ago in 1785, antiarrhythmic drug therapy has advanced considerably and become a cornerstone of AF clinical management. Yet, a preventive or curative panacea for sustained AF does not exist despite the rise of AF global prevalence to epidemiological proportions. While multiple elevated risk factors for AF have been established, the natural history and etiology of AF remain incompletely understood. In the present article, the first section selectively highlights some disappointing shortcomings and current efforts in antiarrhythmic drug therapy to uncover reasons why AF is such a clinical challenge. The second section discusses some modern takes on the natural history of AF as a relentless, progressive fibro-inflammatory “atriomyopathy.” The final section emphasizes the need to redefine therapeutic strategies on par with new insights of AF pathophysiology.

Keywords: atrial fibrillation, a-fib, afib, antiarrhythmic, antiarrhythmic drug therapy, paroxysmal AF, persistent AF, permanent AF

INTRODUCTION

Atrial fibrillation (AF) is the most common sustained arrhythmia with rising global prevalence and a 37% lifetime risk. In AF, the chaotic rapid atrial excitation renders atrial contractions ineffective and ventricular contractions irregularly irregular. The resulting hemodynamic disturbances in AF lead to deleterious clinical consequences. Blood stagnation and flow turbulence in the fibrillatory atrium increase the risk of stroke by five-fold (Wolf et al.,

Abbreviations: ACC, American College of Cardiology; ADT, antiarrhythmic drug therapy; AF, atrial fibrillation; AHA, American Heart Association; CaMKII, Ca²⁺/calmodulin kinase type II; CCB, Ca²⁺ channel blocker; CFAEs, complex fractionated atrial electrograms; dV/dt_{max}, maximum upstroke velocity; ECGI, electrocardiographic imaging; ERP, effective refractory period; ESC, European Society of Cardiology; FDA, Food and Drug Administration; FIRM, focal impulse and rotor modulation; G_s, stimulatory G-protein; hERG, human *ether-a-go-go*-related gene; HFpEF (HFrEF), heart failure with preserved (reduced) ejection fraction; I_{CaL}, L-type Ca²⁺ current; I_f, funny current; I_{K1}, inward rectifier current; I_{K2P}, two-pore-domain K⁺ current; I_{KACH}, acetylcholine-activated inward-rectifier K⁺ current; I_{Kr}/I_{Kur}, rapid/ultrarapid delayed rectifier K⁺ current; (late) I_{Na}, (late) Na⁺ current; I_{SK}, small-conductance Ca²⁺-activated K⁺ current; I_{ss}, steady-state current; LVEF, left ventricular ejection fraction (LVEF)LGE-MRI, late-gadolinium enhancement magnetic resonance imaging; LLTS, low-level tragus electrical stimulation; LLVS, low-level vagus nerve stimulation; miRNA, microRNA; Nav1.5, voltage-gated sodium channel; NCX, Na⁺-Ca²⁺ exchanger; NF-κB, nuclear factor κ-light-chain-enhancer of activated B cells; RAAS, renin-angiotensin-aldosterone system; RyR2, ryanodine receptor; SERCA2a, sarcoplasmic reticulum Ca²⁺-ATPase 2a; siRNA, small interfering RNA; SK, small-conductance Ca²⁺-activated K⁺ channel; TASK-1/-3, two-pore-domain Weak Inward rectifying K⁺ channel (TWIK)-related Acid-Sensitive K⁺ channel-1/-3.

TABLE 1 | Old and current Atrial Fibrillation antiarrhythmic drugs: therapeutic mechanisms and benefits.

| Vaughan Williams class | Targets | Therapeutic mechanisms | Therapeutic benefits for Atrial Fibrillation |
|--|--|---|--|
| Voltage-gated Na⁺ channel blockers | | | |
| IA | Nav1.5 | Open-state I _{Na} block Intermediate offset kinetics | <u>Rhythm control</u> ↓ atrial ectopic automaticity ↓ atrial excitability ↓ atrial conduction ↓ Purkinje conduction ↓ reentrant arrhythmias |
| Quinidine | | | |
| Procainamide | | ↓ peak I _{Na} → ↓ non-AVN dV/dt _{max} , ↑ excitation threshold | |
| Disopyramide | | | |
| | K ⁺ channels | ↓ multiple I _K 's (I _{to} , I _{Kr} , I _{Ks} , I _{K1} , I _{KATP}) | ↑ atrial ERP ↑ atrial APD |
| IC | Nav1.5 | Inactivated-state, frequency-dependent I _{Na} block | <u>Rhythm control</u> |
| Flecainide | SR RyR2-Ca ²⁺ channels | Slow offset kinetics | ↑ potency at rapid heart rates |
| Propafenone | | ↓ peak I _{Na} → ↓↓ dV/dt _{max} (non-AVN APs), ↑ excitation threshold ↓ RyR2-mediated SR Ca ²⁺ release → ↓ intracellular Ca ²⁺ load | ↓ atrial ectopic automaticity ↓ atrial excitability ↓ DAD-induced triggered activity Converts unidirectional to bidirectional block → ↓ reentrant arrhythmias ↓ atrial conduction ↓ accessory pathway conduction ↑↑ atrial APD at rapid heart rates |
| β-Blockers | | | |
| IIA | | ↓ G _s -AC-cAMP signaling → ↓ I _f and ↓ I _{CaL} → ↓ RyR2-mediated SR Ca ²⁺ release, ↓ intracellular Ca ²⁺ load | <u>Rate control</u> ↓ SAN automaticity and ↑ PR ↓ atrial ectopic automaticity ↓ EAD- and DAD-induced triggered activity ↓ AVN conduction ↑ AVN refractoriness ↑ RR ↓ reentrant arrhythmias Prevention of adrenergic AF 1st-line for HFpEF and HFrEF |
| <u>Non-selective</u> | Non-selective β-adrenoceptors | | |
| Carvedilol | | | |
| Propranolol | | | |
| Nadolol | | | |
| <u>Selective</u> | β1-adrenoceptors | | |
| Atenolol | | | |
| Bisoprolol | | | |
| Esmolol | | | |
| Metoprolol | | | |
| Na⁺-K⁺ pump inhibitor | | | |
| IID | Muscarinic M ₂ receptors (SAN, atrial, AVN) | ↑ vagal tone | <u>Rate control</u> ↓ SAN automaticity ↓ AVN conduction ↑ AVN refractoriness Second-line for HFrEF |
| Digoxin | Na ⁺ -K ⁺ pump | ↓ sympathetic tone Hyperpolarizing SAN | |
| Voltage-gated K⁺ channel blockers | | | |
| III | Nonselective K ⁺ channels | ↓ multiple I _K 's (I _{to} , I _{Ks} , I _{K1} , I _{KACH}) | <u>Rhythm control</u> ↑ APD ↑ atrial ERP ↓ reentrant arrhythmias ↓ SAN automaticity (amiodarone) ↓ AVN conduction (amiodarone) |
| <u>Non-selective</u> | | | |
| Amiodarone | | | |
| Dronedarone | | | |
| <u>Selective</u> | Kv11.1 (hERG) | ↓ I _{Kr} | |
| Sotalol | | | |
| Dofetilide | | | |

(Continued on following page)

TABLE 1 | (Continued) Old and current Atrial Fibrillation antiarrhythmic drugs: therapeutic mechanisms and benefits.

| Vaughan Williams class | Targets | Therapeutic mechanisms | Therapeutic benefits for Atrial Fibrillation |
|---|------------------|---|--|
| Voltage-gated Ca²⁺ channel blockers | | | |
| IV | Cav1.2 Cav1.3 | ↓ I _{CaL} → ↓ RyR2-mediated SR Ca ²⁺ release, ↓ intracellular Ca ²⁺ load | Rate control ↓ SAN automaticity ↑ atrial ERP ↓ AVN conduction ↓ EAD- and DAD-induced triggered activity ↓ reentrant arrhythmias |
| Diltiazem | | | |
| Verapamil | | | |

AC, adenylyl cyclase; AF, atrial fibrillation; AP, action potential; APD, action potential duration; AVN, atrioventricular node; cAMP, cyclic adenosine monophosphate; dV/dt_{max}, maximum action-potential upstroke velocity; EAD/DAD, early/delayed afterdepolarizations; ERP, effective refractory period; G_s, stimulatory G protein; HFpEF (HFREF), heart failure with preserved (reduced) ejection fraction; RyR2, ryanodine receptor two; SAN, sinoatrial node; SR, sarcoplasmic reticulum.

1991), heart failure by three-fold (Stewart et al., 2002), dementia by two-fold (Ott et al., 1997), and death by two-fold (Stewart et al., 2002). The rapid ventricular response in AF often causes symptoms and if left untreated, prolonged tachycardia can induce cardiomyopathy over time (Nerheim et al., 2004). Even when the ventricular response is normal or slow, AF can still cause symptoms that limit exercise tolerance and reduce quality of life. While there was just under half a million of AF-related hospitalizations in the United States in 2010 (Patel et al., 2014), this number has been increasing with each subsequent year (Nisar et al., 2016). AF treatment costs \$26 billion annually in the United States alone (Kim et al., 2011; Rozen et al., 2018) and this financial burden will continue to rise as AF soars to epidemic proportions.

Since the first recognition of AF in animals 392 years ago by William Harvey in 1,628 (McMichael, 1982) and since the first ECG depiction of AF in humans 113 years ago by Willem Einthoven in 1906 (Einthoven, 1906; Silverman, 1994), several pathogenic mechanisms have been proposed (Burstein and Nattel, 2008; Greiser et al., 2011). Elevated risk factors for AF were established (January et al., 2014), with advancing age as the most prominent of all (Benjamin et al., 1994; Schnabel et al., 2015). In the United States, extended longevity from medical advances has led to the projection of up to 15 million patients diagnosed with AF by 2050 (Miyasaka et al., 2006; Colilla et al., 2013). Modifiable risk factors for developing AF within 10 years (Schnabel et al., 2009) include hypertension, diabetes mellitus (Patel et al., 2014), coronary artery disease (Peigh et al., 2020), heart failure, obesity (Thacker et al., 2013), and obstructive sleep apnea (Youssef et al., 2018). Non-modifiable AF risk factors include valvular heart disease (Banerjee et al., 2019), hypertrophic cardiomyopathy (Olivotto et al., 2001), and congenital heart disease (Hu and Lin, 2019). The lifetime AF risk of 20% for a patient without risk factors rises to 38% in the presence of just one elevated risk factor (Staerk et al., 2018).

In the interim period between the first pharmacological therapy for heart failure-associated AF using the digitalis leaf 234 years ago by William Withering in 1785 (Withering, 1785; Wray et al., 1985) and the explosive growth of catheter ablation therapy for AF in the last decade, several additional antiarrhythmic drugs have been developed. Yet, none has translated into significant gains in AF clinical management. With each new antiarrhythmic drug discovery, hopes for an effective and safe AF panacea rose, but soon ebbed away. However, despite all its limitations during more than two centuries to prevent or permanently cure AF, antiarrhythmic drug therapy has been and will remain a cornerstone of AF clinical management.

Review Scope

In this primarily pharmacological review, our goal is to examine the benefits (Table 1) and limitations (Table 2) of early, current, and emerging antiarrhythmic drug therapy for AF control. We will also examine the translation gap between the latest mechanistic insights and the presently outdated therapeutic

TABLE 2 | Old and current Atrial Fibrillation antiarrhythmic drugs: therapeutic mechanisms and benefits.

| Vaughan Williams class | Targets | Proarrhythmic mechanisms | Proarrhythmic risks |
|---|--|---|---|
| Voltage-gated Na⁺ channel blockers | | | |
| IA | Nav1.5 | ↓ ventricular I _{Na} | No atrial selectivity |
| Quinidine | | | ↓ ventricular conduction |
| Procainamide | K ⁺ channels | ↓ ventricular I _K | ↑ ventricular APD → ↑ EAD-mediated triggered activity |
| Disopyramide | | | ↑ ventricular ERP |
| | Vagal efferent nerves (SAN, AVN) | Anticholinergic activity (SAN, AVN) | ↑ QT → VT/torsades de pointes |
| | | | ↑ SAN automaticity |
| | | | ↑ AVN conduction → Rapid ventricular response |
| | | | ↑ digoxin toxicity (quinidine) |
| IC | Nav1.5 | Frequency-dependent I _{Na} block | No atrial selectivity |
| Flecainide | K ⁺ channels | ↓ ventricular I _K | ↑ toxicity at rapid heart rates |
| Propafenone | | | ↓ ventricular conduction |
| | | | ↑ ventricular APD |
| | | | ↑ ventricular QRS |
| | | | ↑ VT/sudden cardiac death (flecainide) |
| β-Blockers | | | |
| IIA | Non-selective β-adrenoceptors | ↓ AVN/ventricular I _{CaL} | No atrial selectivity |
| <u>Non-selective</u> | | | |
| Carvedilol | | | Bradycardia |
| Propranolol | | | AV block |
| Nadolol | | | ↑ vagally-mediated AF |
| <u>Selective</u> | | | |
| Atenolol | β1-adrenoceptors | | ↓ myocardial contractility |
| Bisoprolol | | | upregulation of β-adrenoceptors with chronic use |
| Esmolol | | | β-blocker withdrawal |
| Metoprolol | | | |
| Na⁺-K⁺ pump inhibitor | | | |
| IID | Na ⁺ -K ⁺ pump | ↑ sympathetic tone at high doses | No atrial selectivity |
| Digoxin | Muscarinic M ₂ receptors (SAN, atrial, AVN) | | ↓ atrial ERP (small effect) |
| | | | Narrow therapeutic window |
| | | | ↑ AV block |
| | | | ↑ DAD-mediated triggered activity |
| | | | ↑ VT and arrhythmic death |
| Voltage-gated K⁺ channel blockers | | | |
| III | K ⁺ channels | ↓ ventricular I _{Kr} | ↑ ventricular APD → ↑ EAD-mediated triggered activity |
| Sotalol | | | ↑ QT → VT/torsades de pointes |
| Dofetilide | | | ↑ QRS |
| Amiodarone | | | Ashman phenomenon |
| Dronedarone | | | |
| Voltage-gated Ca²⁺ channel blockers | | | |
| IV | Cav1.2 | ↓ I _{CaL} | No atrial selectivity |
| Diltiazem | Cav1.3 | | Bradycardia |
| Verapamil | | | AV block |
| | | | ↑ rapid ventricular response in AF with WPW syndrome |

AF, atrial fibrillation; APD, action potential duration; AV(N), atrioventricular (node); EAD/DAD, early/delayed afterdepolarizations; ERP, effective refractory period; G_s, stimulatory G protein; I_{CaL}, L-type Ca²⁺ current; I_{Kr}, rapid delayed rectifier current, SAN, sinoatrial node; VT, ventricular tachycardia; WPW, Wolff-Parkinson-White.

paradigms. We will not acute management of the first AF occurrence or anticoagulant therapy for AF-related stroke prevention. Nor will we discuss antiarrhythmic therapy for lone AF, postoperative AF, AF precipitated by acute precipitating illnesses, or atrial flutter. Instead, we will review some prominent antiarrhythmic drug therapies for recurrent AF. We will focus particularly on the antiarrhythmic drugs featured in selected landmark AF clinical trials that shifted therapeutic paradigms and shaped management guidelines. We will emphasize why we must understand AF natural history to redefine strategies for antiarrhythmic drug development.

EARLY ANTIARRHYTHMIC DRUGS FOR RHYTHM CONTROL

Historically, the therapeutic approach was a “one-fits-all” paradigm that focused on the antiarrhythmic drugs rather than on the patients’ AF. The classical concept of an ideal pharmacotherapy for AF is an antiarrhythmic drug that can restore and maintain sinus rhythm with minimal or acceptable systemic side effects. In the 20th century, while both rhythm control and rate control were generally acceptable strategies for long-term AF management, the rhythm control strategy, which relies on cardioversion and antiarrhythmic drug therapy, was by

far the preferred initial therapy. Classical AF antiarrhythmic drugs most commonly target ion channels for current inhibition rather than current augmentation (Table 1). Unfortunately, because these ion channel blockers commonly lack exquisite target specificity, they block both atrial and ventricular ion channels. As a result, adverse effects, largely from ventricular ion channel blockade (Table 2), often blunt atrial therapeutic benefits (Table 1).

Class IA Drugs (Quinidine, Procainamide, Disopyramide)

Quinidine, one of the oldest antiarrhythmic drugs, was used extensively in the 20th century for a variety of arrhythmias, including AF (Askey, 1946; McMillan and Welfare, 1947; Wegria, 1947). The combination of quinidine and verapamil has similar efficacy in preventing AF recurrences as sotalol but with better safety profile (Fetsch et al., 2004; Patten et al., 2004).

Procainamide and disopyramide came next on the market as promising new agents for AF in the mid-1900s (McCord and Taguchi, 1951; Miller et al., 1952; Hartel et al., 1974). Classified as Vaughan Williams class IA, quinidine, procainamide, and disopyramide block not only Na⁺ channels, but also K⁺ channels, thereby prolonging effective refractory period (ERP) (Vaughan Williams, 1984). ERP prolongation is beneficial in reducing susceptibility to reentry and therefore AF recurrences.

However, the lack of atrial selectivity of these antiarrhythmics contributes to QRS and QT prolongation, thereby increasing the risk of torsades de pointes, a most serious adverse effect that can lead to sudden cardiac arrest. There is also evidence that class IA drugs, especially disopyramide, decrease vagal tone by inhibiting cholinergic activity, which may require the concomitant use of β -blockers or Ca²⁺ channel blockers (Warrington and Hamer, 1980; Nakajima et al., 1989). For example, thanks to its negative inotropy, disopyramide received class IIa recommendation with level of evidence C for maintenance of sinus rhythm in AF patients with underlying hypertrophic cardiomyopathy, but must be used in conjunction with a β -blocker or nondihydropyridine Ca²⁺ channel blocker (January et al., 2014).

Thus, despite moderate efficacy in preventing AF recurrences, clinical adverse events, especially ventricular proarrhythmia and resultant increased mortality (quinidine and disopyramide), mar the safety profile of these class IA rhythm-control drugs (Lafuente-Lafuente et al., 2015).

EVOLVING THERAPEUTIC STRATEGIES

The 21st century marks critical milestones that shifted existing therapeutic paradigms and shaped management guidelines. The first milestone came in 2001, when the ACC, the AHA, and the European Society of Cardiology (ESC) jointly established a unified classification scheme for AF (Fuster et al., 2001; Calkins et al., 2007). Nonsustained recurrent AF is designated “paroxysmal” if AF does not sustain past 7 days. Past 7 days, AF is considered sustained. Sustained AF is designated “persistent” if

not lasting longer than 1 year, “longstanding persistent” if lasting longer than 1 year (Calkins et al., 2007; Kirchhof et al., 2016), and “permanent” if rhythm control is unsuccessful or not attempted. Permanent AF is reclassified as longstanding persistent if a rhythm control strategy is adopted after 1 year of continuous AF. By separating AF presentations based on their temporal heterogeneities, this classification scheme marked an important shift in the therapeutic paradigm. The classical “one-fits-all,” drug-centered approach was replaced by the modern arrhythmia-centered realization that no single therapeutic strategy best serves all AF classes. Different AF classes are associated with different prognoses and require different therapeutic strategies, such as rhythm vs. rate control, pharmacological vs. non-pharmacological intervention (Table 3).

The next milestone came from the revolutionary insights of the *Atrial Fibrillation Follow-up Investigation of Rhythm Management* (AFFIRM) (Wyse et al., 2002; Corley et al., 2004), the largest randomized controlled clinical trial at the time ($n = 4,060$ AF patients; 4-years follow up). The goal of the AFFIRM trial was to address the controversy of anticoagulated rhythm control vs. anticoagulated rate control as the main long-term therapeutic strategy with superior survival benefits. The AFFIRM trial revealed that while rhythm control improved survival, the existing antiarrhythmic drugs themselves did not improve survival because adverse effects of the drugs offset any survival benefits by the drugs in maintaining sinus rhythm (Corley et al., 2004). Therefore, antiarrhythmic drug therapies achieved similar outcomes with either the rhythm-control or the rate-control strategy. Nonetheless, this trial contributed in shifting the therapeutic paradigm from prior rhythm control to rate control as the main strategy.

However, improved survival is only one of the two primary clinical outcome endpoints in AF clinical management. The other primary therapeutic outcome is improved quality of life. Following the AFFIRM trial, multiple other randomized controlled trials addressed the question whether rhythm control or rate control was the strategy to superior improvement in quality of life. For example, the *Controlled Study of Rate vs. Rhythm Control in Patients with Chronic AF and Heart Failure* (CAFÉ-II) found that the rhythm-control strategy, even when achieved by an antiarrhythmic drug such as amiodarone, was associated with greater symptomatic relief and improved quality of life as compared to the rate-control strategy (Shelton et al., 2009).

Although an in-depth discussion of non-pharmacological interventions to control AF is beyond the scope of this pharmacological review, a brief comparison of the different merits and shortcomings of pharmacological and non-pharmacological approach, most notably catheter ablation, is warranted.

Overall, non-pharmacological interventions for AF has evolved a long way from electrical cardioversion and surgical ablation to device-based therapy with Holter or pacemaker telemonitoring and catheter ablation. The first non-pharmacological intervention for AF was electrical cardioversion to defibrillate the atria for rhythm control of non-persistent AF or symptomatic management, but its

TABLE 3 | Management strategy for recurrent Atrial Fibrillation based on episode duration.

| AF classification | Paroxysmal | Persistent ^a | Permanent ^a |
|---------------------------------|-----------------------------------|-------------------------------------|-----------------------------------|
| AF episode duration | ≤7 days | >7 days and ≤1 year | Typically >1 year |
| Structural remodeling | Atrial fibrosis | Atrial fibrosis | Atrial and ventricular fibrosis |
| Severity | Minimal to mild | Mild to moderate | Moderate to severe |
| Electrical remodeling | Pulmonary veins | Atria | Atria |
| Severity | Focal | Diffuse | Diffuse |
| Pathology | Minimal | Atrioamyopathy | Cardiomyopathy |
| Main strategy | Rhythm control | Rhythm or rate control ^b | Rate control only |
| First-line therapy ^b | Catheter ablation | Antiarrhythmic drugs ^c | Antiarrhythmic drugs ^d |
| Second-line therapy | Antiarrhythmic drugs ^c | Catheter ablation | N/A |

AF, atrial fibrillation.

^aLongstanding persistent AF straddles persistent and permanent AF because cardiac remodeling severities and pathology resemble those in permanent AF, but rhythm-control strategy is an option.

^bExceptions: other clinical factors for considerations, such as drug side effect profile, tolerability, and ease of administration or patients' age, therapeutic preferences, therapeutic contraindications, and comorbidities (hemodynamic status, ongoing myocardial infarction, hypotension, decompensated heart failure, pre-excitation, hypertrophic cardiomyopathy, other structural heart abnormalities unrelated to AF, etc.).

^cFor rhythm or rate control.

^dFor rate control only.

recent use as a diagnostic rather than therapeutic procedure has emerged. To the same end, implantable atrial defibrillator (IAD) for symptomatic, drug-refractory AF was evaluated in a multicenter study ($n = 136$ patients, 40-months median follow-up) but long-term outcome was not encouraging (Geller et al., 2003). Next, instead of atrial defibrillation, permanent atrial pacing to prevent and/or terminate AF has been explored, but there is insufficient evidence to support recommendation for AF therapy unless otherwise indicated for symptomatic bradycardia or sick sinus syndrome (Ellenbogen, 2007).

In the interim, ablation of AF has evolved from the first classical labyrinth Cox-Maze open-heart surgery with cardiopulmonary bypass support in 1987 to less invasive surgical and particularly catheter procedures. Various energy sources (such as cryothermia or ultra-low temperature cryoablation, unipolar or bipolar radiofrequency, microwave, laser, ultrasound, or electroporation) have been experimented to effectively and safely cause atrial myocyte death in a contiguous, transmural, permanent, and linear fashion. The goal of AF ablation is to electrically isolate common sites of triggers that initiate and/or maintain AF. The most common targets for ablation are the pulmonary veins (Haissaguerre et al., 1998) and left atrial appendage (Di Biase et al., 2010; Hocini et al., 2011); less common targets include the left atrial roof, mitral valve isthmus, and atrioventricular junction. Various refinements beyond pulmonary vein isolation, including complex fractionated atrial electrograms (CFAEs), focal impulse and rotor modulation (FIRM), electrocardiographic imaging (ECGI), have been explored but met with variable, inconsistent success (Weiss et al., 2016). For left atrial appendage occlusion, the AtriClip device has gained increasing popularity over the last decade as a safe and efficacious alternative to surgical closure and can be easily deployed during concomitant open chest surgery or stand-alone minimally invasive procedure (Ellis et al., 2017; Caliskan et al., 2018; Toale et al., 2019).

Taken together, while antiarrhythmic drug therapy repeatedly fell short of efficacy and safety expectations, the last 2 decades and particularly the last 5 years mark a revolutionizing milestone in non-pharmacological interventions for rhythm control with tremendous advances in AF catheter ablation (Kuck et al., 2016). For example, the *Catheter Ablation vs. Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation* randomized clinical trial (CASTLE-AF; $n = 363$ patients, 37.8-months median follow-up) (Marrouche et al., 2018) showed that AF catheter ablation led to reduced overall mortality and heart failure-related hospitalizations. Despite all the controversies that it generated, CASTLE-AF contributed to the most recent clinical guideline revision. In early July 2019, the AHA/ACC/HRS published a focused update containing only one revision for rhythm control maintenance: a new, weak class IIb recommendation with level of evidence B-R for AF catheter ablation in heart failure (January et al., 2019).

However, concerning the two primary endpoints of improved survival and improved quality of life, catheter ablation has not yet proven superior to antiarrhythmic drug therapy as demonstrated by the *Catheter Ablation vs. Antiarrhythmic Drug Therapy for AF* randomized clinical trial (CABANA; $n = 2,204$ patients; 5-years follow up) (Moreno and Zamorano, 2014; Packer et al., 2018). In addition, AF catheter ablation faces its own host of considerable limitations, such as higher costs, limited availabilities of skilled electrophysiologists and experienced centers, procedural risks, and patients' ablation candidacy, to name just a few. Thus, aside from patients' own values and preferences for a pharmacological vs. non-pharmacological approach, expert consensus in both the ESC and AHA/ACC/HRS guidelines indicates a stronger class of recommendation for catheter ablation to maintain sinus rhythm in the presence of three critical variables: symptomatic recurrences, AF class (≤80% success rate for *paroxysmal* vs. ≤50% for *persistent and longstanding persistent*) (Kirchhof et al., 2016; Calkins et al., 2018), and heart failure (class of recommendation IIb) (January et al., 2019).

TABLE 4 | Antiarrhythmic drug recommendations for ventricular rate control since 2014.^a

| Comorbidities | No other CV disease | Hypertension HFpEF | HFrEF | COPD |
|---------------|---------------------|--------------------|-------------|------------|
| β-Blocker | First-line | First-line | First-line | First-line |
| Diltiazem | First-line | First-line | — | First-line |
| Verapamil | First-line | First-line | — | First-line |
| Digoxin | — | — | Second-line | — |
| Amiodarone | Second-line | Second-line | Second-line | — |

CV, cardiovascular; HFpEF, heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; COPD: chronic obstructive pulmonary disease.

^aBased on the 2014 AHA/ACC/HRS guideline for atrial fibrillation management (January et al., 2014).

CURRENT ANTIARRHYTHMIC DRUGS FOR RATE CONTROL

Recommendations for antiarrhythmic drug therapy for the ventricular rate-control strategy have not changed (January et al., 2019) since the 2014 AHA/ACC/HRS guideline and are summarized in **Table 4** (January et al., 2014). For ventricular rate-control of AF patients with preserved left ventricular ejection fraction (LVEF), β-blockers and nondihydropyridine Ca²⁺-channel blockers (CCBs) remain first-line therapies, but differences between their mechanisms of action and pharmacokinetics lead to differences in therapeutic applications. For AF patients with reduced LVEF, β-blockers are the only first-line rate-control drugs whereas CCBs are contraindicated.

Class IIA Drugs (β-Blockers)

The β-adrenergic system is an important regulator of the L-type Ca²⁺ current (I_{CaL}). Cardiac β-adrenoceptors (80% β₁, 20% β₂) belong to the G protein-coupled receptor superfamily. β-Blockers slows ventricular response in AF by indirect inhibition of I_{CaL} via competitive inhibition with β-agonists for binding to β-adrenoceptors. Binding of β-agonists to β-adrenoceptors activates stimulatory G-proteins (G_s) that activate adenylyl cyclase to generate cyclic adenosine monophosphate (cAMP), which in turn activates protein kinase A to phosphorylate phospholamban, ryanodine receptors, myofilament proteins, and L-type Ca²⁺ channels, thereby increasing I_{CaL}. Binding of β-blockers to β-adrenoceptors prevents β-agonists from binding and activating G_s-dependent signaling. Because the β-blocker dose-response curve for rate control is relatively flat over the clinically-relevant dose range, once the high dose-range is reached, further dose up-titration produces only minimal gains in additional heart rate reduction but can substantially increase the likelihood of adverse events (hypotension). In that case, another drug class should be added.

Class IID Drugs (Digoxin)

Digoxin has a direct action on the myocardium and an indirect action on the autonomic nervous system. Digoxin directly blocks the myocardial Na⁺ -K⁺ pump, leading to increased intracellular Ca²⁺ and slightly improved cardiac contractility. However, more prominent and relevant to AF rate control, digoxin indirectly modulates the electrophysiology of the atria, sinoatrial node, and particularly atrioventricular node by modulating the cardiac autonomic nervous system. In AF patients without heart failure, the indirect neural action of digoxin predominates because it is more robust and occurs at lower therapeutic doses (Watanabe, 1985). This explains why digoxin toxicity in the whole animal results primarily from the indirect neural effect but in the isolated heart from the direct myocardial effect (Levitt et al., 1976b). Of note, in heart failure, because baseline vagal tone is reduced and sympathetic tone is increased, the direct myocardial action of digoxin may predominate (Goodman et al., 1975; Watanabe, 1985).

Interestingly, the mechanisms underlying the pharmacodynamics effects of digoxin on the atrioventricular node caused quite a controversy, but they highlight both the influence of digoxin on the autonomic nervous system and the complex contributions of the autonomic nervous system to AF pathogenesis. Digoxin minimally modulates the electrophysiology of the atria (by reducing atrial refractoriness) and the sinoatrial node (by depressing its activity). In contrast, digoxin exerts profound vagomimetic and small sympatholytic effects on the atrioventricular node, leading to marked increase of atrioventricular nodal refractoriness. This results in reduced impulse conduction to the ventricles and slowing of ventricular response (Goodman et al., 1975; Watanabe, 1985). An important clinical implication is that because the therapeutic mechanism of digoxin depends on intact rich autonomic innervation of the atrioventricular node; its rate-control effect will be attenuated during exercise (that causes withdrawal of vagal tone), blunted in failing hearts, and ineffective in denervated transplanted hearts (Goodman et al., 1975).

Another important clinical implication is that the synergistic or antagonistic interactions of digoxin with other drugs that also act on the autonomic nervous system may potentially lead to disastrous clinical consequences. For example, the potent anticholinergic activity of Class IA antiarrhythmic drugs may antagonize the vagal stimulation by digitalis, potentially leading to deleterious increases in ventricular response. On the other hand, the antiadrenergic activity of β-blockers and other antihypertensive drugs may potentiate the sympathetic inhibition by digoxin, leading to excessively slow ventricular response or even atrioventricular block with resultant fatigue, syncope, or even sudden death. Likewise, the impairment of atrioventricular conduction by Ca²⁺-channel blockers may potentiate that by digoxin, leading to dangerously slow ventricular response (Watanabe, 1985).

A most important digoxin cardiotoxicity is cardiac arrhythmias, typically in the form of atrioventricular block with or without enhanced automaticity. Additionally, although at therapeutic doses the predominant action of digoxin is vagal stimulation, at high doses digoxin action may paradoxically

switch from sympathetic inhibition to sympathetic stimulation, potentially causing lethal ventricular tachyarrhythmias (Watanabe, 1985).

Class IV Drugs (Nondihydropyridine Ca^{2+} -Channel Blockers)

I_{CaL} contributes to the upstroke of atrioventricular-node action potentials. Unlike β -blockers, CCBs inhibit I_{CaL} directly by binding to L-type Ca^{2+} channels. Therefore, while both β -blockers and CCBs block I_{CaL} , the difference in their mechanisms of action allows synergism. In contrast to the flat β -blocker dose-response curve, the CCB dose-response curve is relatively linear over the clinically relevant dose range. Therefore, CCB dose up-titration produces appreciable gains in additional ventricular rate reduction throughout the full therapeutic range. In a head-to-head comparative clinical trial of emergency patients presenting with AF and rapid ventricular response, diltiazem achieves rate-control targets faster without any increase in adverse events compared to metoprolol (Fromm et al., 2015).

CURRENT ANTIARRHYTHMIC DRUGS FOR RHYTHM CONTROL

Recommendations for antiarrhythmic drug therapy for the rhythm control strategy have not changed (January et al., 2019) since the 2014 AHA/ACC/HRS guideline (Table 5) (January et al., 2014).

Class IC Drugs (Flecainide, Propafenone)

Both flecainide and propafenone are recommended first-line therapy for AF patients with no structural heart disease to restore sinus rhythm acutely or to maintain sinus rhythm long-term (Anderson et al., 1989; Meinertz et al., 2002). These two potent Na^+ channel blockers slow atrial conduction, thereby reducing atrial automaticity and excitability. Due to their frequency dependence, their potency and, unfortunately, their proarrhythmic toxicity increase with rapid heart rates. Because these drugs lack atrial selectivity, they also act on the ventricular tissue to prolong both action potential and QRS. A QRS prolongation of 25% on therapy over baseline would require dose reduction or drug discontinuation due to the risk of lethal ventricular tachyarrhythmias and hemodynamic collapse. In fact, the contraindication of these drugs in structural heart disease stems from the demonstration of increased mortality associated with flecainide in the *Cardiac Arrhythmia Suppression Trial* (CAST) (Echt et al., 1991; Anderson et al., 1994). Due to similar concern for increased risk of sudden cardiac death, another important contraindication is the congenital loss-of-function Na^+ channel mutations, such as in Brugada syndrome.

Class III Drugs (Sotalol, Dofetilide, Amiodarone)

Together with flecainide and propafenone, sotalol is also indicated first-line therapy in the maintenance of sinus

rhythm for AF patients with no structural heart disease (Camm et al., 2010; Fuster et al., 2011). The antiarrhythmic benefit for AF and proarrhythmic toxicity of the class III drugs come from their potency in prolonging the action potential and refractoriness of the atria and ventricles, respectively.

Sotalol is particularly potent and proarrhythmic at slower heart rates due to its reverse frequency dependence. Thus, unlike the frequency-dependent class IC antiarrhythmics (flecainide) that are effective in terminating AF, the reverse-frequency dependent class III antiarrhythmics like sotalol and dofetilide are ineffective in terminating AF, but effective in preventing AF. One randomized placebo-controlled clinical trial ($n = 300$ patients with recurrent symptomatic AF; 1-year follow up) found that sotalol and propafenone are equally effective in maintaining sinus rhythm (73 and 63%, respectively), both being superior to placebo (35%) (Bellandi et al., 2001). However, only sotalol caused malignant proarrhythmia (4%) within 72 h of therapy initiation (Bellandi et al., 2001). Due to the lack of atrial selectivity, the class III proarrhythmic toxicity of sotalol relates to its potency in prolonging the QT interval, resulting in its propensity to cause torsades de pointes. The higher the dose and the slower the heart rate, the higher the risk of severe QT prolongation and consequently the higher the risk of torsades de pointes and mortality (Lafuente-Lafuente et al., 2015).

Whereas sotalol has mixed non-cardioselective β -blocking property, dofetilide is a “pure” class III antiarrhythmic, blocking only the voltage-gated K^+ channels. Dofetilide was approved by United States Food and Drug Administration (FDA) for use in the United States in 1999 for AF patients without structural heart disease and without severely diminished creatinine clearance. Due to reverse-frequency dependence, dofetilide is more effective in maintaining sinus rhythm than in cardioverting AF as demonstrated by the *Symptomatic AF Investigative Research on Dofetilide* (SAFIRE-D) study (Singh et al., 2000). However, as with sotalol, because dofetilide causes dose-dependent QT prolongation, its major proarrhythmic toxicity is torsades de pointes. With incidence of dofetilide-associated torsades de pointes reportedly as high as 4.7%, drug initiation requires inpatient monitoring and certified physicians.

Amiodarone, an iodinated benzofuran derivative, is the most widely used off-label antiarrhythmic for AF due to its superior efficacy in both cardioversion (Khan et al., 2003) and particularly sinus rhythm maintenance (Roy et al., 2000; Wyse et al., 2002; Singh et al., 2005; Freemantle et al., 2011). Amiodarone displays properties of all four Vaughan Williams classes, but is classified as class III due to its major potency in blocking K^+ channels to prolong cardiac action potential and refractoriness. Therefore, amiodarone also causes QT prolongation, but not torsades de pointes, probably because it also inhibits multiple other ion channels. Although a major cardiac adverse effect of amiodarone is sinus bradycardia, the use of amiodarone is unfortunately limited by a plethora of non-cardiac toxicities, attributed to the progressive accumulation of its damaging metabolite desethylamiodarone in multiple organs including the lungs, thyroid, liver, as well as the central nervous system. Amiodarone also exhibits multiple drug interactions (e.g., with

TABLE 5 | Antiarrhythmic drug recommendations for rhythm control since 2014.^a

| Comorbidities | No structural heart disease | Coronary artery disease | Heart failure |
|---------------------------------------|-----------------------------|-------------------------|---------------|
| Flecainide (class IC) ^{b,c} | First-line | — | — |
| Propafenone (class IC) ^{b,c} | First-line | — | — |
| Sotalol (class III) ^{b,d} | First-line | First-line | — |
| Dronedarone (class III) | First-line | First-line | — |
| Dofetilide (class III) ^{b,d} | First-line | First-line | First-line |
| Amiodarone (class III) | Second-line | Second-line | First-line |

^aBased on the 2014 AHA/ACC/HRS guideline for atrial fibrillation management (January et al., 2014).

^bAvoid in severe left ventricular hypertrophy (wall thickness > 1.5 cm).

^cTo combine with atrioventricular nodal blocking drugs.

^dCaution in high risk for torsades de pointes.

warfarin) due to its inhibition of the cytochrome P450. Therefore, current clinical practice reserves amiodarone for AF with severe left heart failure or for refractory AF when options for other antiarrhythmic drugs have been exhausted.

EMERGING ANTIARRHYTHMIC DRUGS FOR RHYTHM CONTROL

There have been renewed efforts in the 21st century to discover either new antiarrhythmic agents or new synergistic combinations of existing and new agents to improve both efficacy and safety for AF antiarrhythmic drug therapy (Table 6). To this end, the modern mechanistic prototype for the ideal antiarrhythmic drug to control AF should include two critical specificities: first, specificity for the *atrial tissue* (to avoid ventricular proarrhythmia) and second, specificity for *AF pathology*.

The atrial specificity of an antiarrhythmic drug can be enhanced by targeting atrial-predominant currents for blockade, particularly those affected by AF electrical remodeling, such as the ultrarapid delayed rectifier K⁺ current (I_{Kur}), the acetylcholine-activated inward-rectifier K⁺ current (I_{KACH}), the two-pore-domain K⁺ current (I_{K2P}), and the small-conductance Ca²⁺-activated K⁺ current (I_{SK}). The AF-pathology specificity of an antiarrhythmic drug can be enhanced by exploiting the voltage- and frequency dependence of its channel blockade. Because atrial tissue with active AF is typically depolarized and has high frequency of depolarization, the more the drug blocking potency depends on depolarized voltage and high frequency of depolarization, the greater its specificity for AF pathology.

New Class I Drug (Ranolazine)

Ranolazine was initially designed as an anti-ischemic, antianginal drug because it blocks both atrial and ventricular late Na⁺ current (late I_{Na}), which increases pathologically during myocardial ischemia. Increased late I_{Na} is proarrhythmic because the resulting intracellular Na⁺ overload activates Na⁺-Ca²⁺ exchanger (NCX) reverse-mode, causing intracellular Ca²⁺ overload that leads to sarcoplasmic reticulum Ca²⁺ leak, diastolic dysfunction, and increased oxygen demand (Hale et al., 2006; Hale et al., 2008). However, ranolazine anti-AF

efficacy in AF may also be due to its reduction of peak I_{Na} and especially its atrial-selective inhibition of the rapid delayed rectifier K⁺ current (I_{Kr}) carried by Kv11.1, the cardiac human *ether-a-go-go*-related gene (hERG) K⁺ channel. Together, these three mechanisms allow ranolazine to increase atrial postrepolarization refractoriness and slow interatrial conduction without affecting atrial action potential duration (Burashnikov et al., 2007; Kumar et al., 2009; Antzelevitch et al., 2011).

Ranolazine plus amiodarone is one particular combination of antiarrhythmic drug therapy that has shown promising results for synergistic efficacy for conversion of post-cardiac surgery and other recent-onset AF (Koskinas et al., 2014; Simopoulos et al., 2018). For new-onset AF, the combination of ranolazine and amiodarone had higher efficacy in terminating AF than amiodarone alone (Koskinas et al., 2014). Used alone, ranolazine decreased AF recurrence after electrical cardioversion (White and Nguyen, 2017) and reduced the frequency of new onset AF as well recurrences following coronary artery bypass grafting surgery (De Vecchis et al., 2018).

Likewise, the combination of ranolazine and low-dose dronedarone reduced the AF burden (mean duration of AF episodes) by 59% as compared to placebo in the HARMONY clinical trial (Reiffel et al., 2015). The synergistic activity between ranolazine and dronedarone can potentially reduce the dose needed and reduce the adverse effects associated with dronedarone monotherapy.

New Class III Drugs (Dronedarone, Vernakalant, Niferidil)

Dronedarone

Dronedarone is a newer, non-iodinated benzofuran derivative of amiodarone, designed to reduce amiodarone-related non-cardiac toxicities. Iodine moieties were removed to reduce thyroid toxicity. A methylsulfonamide group was added to reduce lipophilicity and consequent accumulation in lipid-rich organs (Zareba, 2006). Disappointingly, comparing with amiodarone, dronedarone efficacy is inferior (Le Heuzey et al., 2010; Freemantle et al., 2011) and its safety profile is different, but not necessarily superior (Hohnloser et al., 2009; Connolly et al., 2011). The most concerning dronedarone non-cardiac toxicity, which received FDA warning, is severe liver injury with rare risk of acute failure requiring transplant.

TABLE 6 | Emergent antiarrhythmic drugs for AF rhythm control: mechanisms and clinical effects.

| Drugs | Targets | Mechanisms | Clinical effects |
|--|---|---|---|
| Ranolazine <i>Vaughan Williams ID</i> | Nav1.5 Kv11.1 (hERG; I_{Kr}) | <u>Therapeutic mechanisms</u> Frequency-dependent block of atrial peak and late I_{Na} → ↓dV/dt _{max} , ↑ diastolic excitation threshold, ↓ Ca^{2+} overload Reverse frequency-dependent block of atrial I_{Kr} → counteracts Ach-induced ↓atrial APD | <u>Therapeutic benefits for AF</u> Atrial-selective effects of I_{Na} block ↓ EAD-induced triggered activity ↑ atrial ERP ↑ atrial postrepolarization refractoriness Frequency-dependent ↑ atrial conduction time ↓ phase-3 EADs, DADs, triggered activity ↓ AF duration ↓ AF dominant frequency → ↑ likelihood of defibrillation success ↓ Ach-mediated AF ↑ atrial APD |
| Vernakalant (RSD1235) <i>Vaughan Williams III</i> | Nav1.5 Atrial K^+ channels Kv1.5 (I_{Kur}), I_{KACH} , I_{to} Other K^+ channels Kv11.1 (hERG; I_{Kr}) | <u>Proarrhythmic mechanisms</u> ↓ ventricular I_{Kr} (mitigated by ↓ ventricular late I_{Na}) <u>Therapeutic mechanisms</u> Atrial-predominant I_{Na} block: Open-state, voltage- and frequency-dependent → ↓ atrial dV/dt _{max} Rapid onset/offset kinetics ↓ late I_{Na} (HEK cells) Open-state ↓ I_{Kur} (HEK cells) ↓ I_{KACH} <u>Proarrhythmic mechanisms</u> ↓ I_{Na} (SAN) ↓ ventricular I_{Kr} (mitigated by ↓ ventricular late I_{Na}) | <u>Proarrhythmic risks</u> Slight ↑ QT (without causing torsades de pointes or ↑transmural dispersion of repolarization) <u>Therapeutic benefits for AF</u> Atrial-selective effects ↓ atrial impulse conduction (at rapid heart rates) ↓ atrial excitability Frequency-dependent ↑ atrial ERP ↑ AVN refractoriness ↑ atrial APD Rapid conversion of recent-onset AF <u>Proarrhythmic risks</u> Sinus bradycardia Slight ↑ QT (without causing torsades de pointes or ↑transmural dispersion of repolarization) |
| Niferidil (RG-2) <i>Vaughan Williams III</i> | K_v 1.5 (atrial-specific) Nav1.5 | <u>Therapeutic mechanisms</u> ↓ I_{Kur} , ↓ I_{KACH} , ↓atrial I_{Kr} Open-state, voltage- and frequency-dependent I_{Na} block Rapid kinetics <u>Proarrhythmic mechanisms</u> ↓ I_{KSS} and ↓ I_{Kur} (murine ventricles) | <u>Therapeutic benefits for AF</u> ↑ atrial APD ↑ atrial ERP ↓ recent-onset AF and ↓ persistent AF <u>Proarrhythmic risks</u> ↑ ventricular APD (mice) |
| Vanoxerine (GBR-12909) <i>DRI</i> | Kv11.1 (hERG; I_{Kr}) Cav1.2 Nav1.5 | <u>Therapeutic mechanisms</u> Strongly frequency-dependent I_{Kr} block > I_{CaL} block > frequency-dependent I_{Na} block <u>Proarrhythmic mechanisms</u> ↓ventricular I_{Kr} | <u>Therapeutic benefits for AF</u> High conversion rate for recent-onset AF <u>Proarrhythmic risks</u> ↑ QT → VT/torsades de pointes? (Conflicting studies) |
| Antazoline <i>First-generation antihistamine (H1-receptor blocker)</i> | Nav1.5? K^+ channels? | <u>Therapeutic mechanisms</u> ↓ I_{Na} ? ↓ I_{Kr} ? <u>Proarrhythmic mechanisms</u> | <u>Therapeutic benefits for AF</u> High conversion rate for PAF ↑ atrial APD ↑↑ atrial ERP ↑ atrial postrepolarization refractoriness ↑ interatrial conduction time <u>Proarrhythmic risks</u> Bradycardia Non-sustained sinus tachycardia |

(Continued on following page)

TABLE 6 | (Continued) Emergent antiarrhythmic drugs for AF rhythm control: mechanisms and clinical effects.

| Drugs | Targets | Mechanisms | Clinical effects |
|---|--|--|---|
| XEN-D0103 (S66913) | Kv1.5 (atrial-specific) | Therapeutic mechanisms ↓ atrial-specific I_{Kur} | Therapeutic benefits for AF: none Atrial-selective ion channel blockade 1 atrial APD |
| A293 | Atrial-specific K2P channels (TASK-1, TASK-3) | Proarrhythmic mechanisms Therapeutic mechanisms ↓ atrial-specific leak current I_{K2P} | No effect on AF burden Proarrhythmic risks: None Therapeutic benefits for AF |
| Doxapram <i>I_{K2P}</i> inhibitors blockers | | Proarrhythmic mechanisms | Atrial-selective ion channel blockade 1 atrial APD 1 atrial ERP Prevents atrial electrical remodeling Proarrhythmic risks: None |

ACS, acute coronary syndrome; AF, atrial fibrillation; AP, action potential; APD, action potential duration; DRI, Dopamine reuptake inhibitor; dV/dt_{max} , maximum action-potential upstroke velocity; EAD/DAD, early/delayed afterdepolarizations; ERP, effective refractory period; PAF, paroxysmal atrial fibrillation; SAN, sinoatrial node; VT, ventricular tachycardia.

Vernakalant (RSD1235)

Another notable contender is vernakalant (RSD1235), a new class III antiarrhythmic drug with frequency- and voltage-dependent blockade. Originally developed for Kv1.5 (I_{Kur}) block to treat AF, vernakalant was shown experimentally to block multiple ion channels, including those mediating I_{Kur} , I_{KACh} , the transient outward K^+ current (I_{to}), I_{Kr} peak and late I_{Na} . Interestingly, vernakalant acts as an atrial-selective antiarrhythmic drug but is not an atrial-selective ion channel blocker. At least two reasons account for its atrial selectivity. First, because the resting membrane potential is more depolarized in the atria than ventricles, plus this voltage difference is further amplified during AF, the dependence of its potency on depolarized membrane voltage confers atrial selectivity. Second, because Kv1.5 channels are detected only in human atria, but not in human ventricles, the blockade of human Kv1.5 by vernakalant is atrial-specific. Aside from its atrial selectivity, its rapid onset and offset kinetics confers a low proarrhythmic risk. Of note, while the Kv1.5 block by vernakalant was demonstrated in Kv1.5-expressing HEK293 cells (Eldstrom et al., 2007) and a rat model of myocardial infarction (Fedida et al., 2005), there has been no evidence yet for Kv1.5 block by vernakalant in human atrial myocytes (Wettwer et al., 2013). Likewise, to date the block of I_{NaL} by vernakalant was demonstrated only in Nav1.5-expressing HEK293 cells and rabbit Purkinje fibers (Fedida et al., 2006; Orth et al., 2006), but not in human atrial tissue (Wettwer et al., 2013).

Instead, the clinical efficacy of vernakalant in acute rhythm control of recent-onset AF is largely attributed to its frequency- and voltage-dependent open-state blockade of Na^+ channels. Nav1.5 block by vernakalant reduces maximum action-potential upstroke velocity (dV/dt_{max}), thereby impairing atrial impulse conduction (Roy et al., 2008; Kowey et al., 2009; Camm et al., 2011). Additionally, its rapid unbinding kinetics of Nav1.5 block by vernakalant contributes to augmenting atrial selectivity and lowering ventricular proarrhythmic risks (Burashnikov and Antzelevitch, 2009).

Multiple placebo-controlled phase 3 studies have demonstrated the superior efficacy of vernakalant in rapid AF cardioversion (8–14 min after the first dose) (Roy et al., 2008; Kowey et al., 2009; Pratt et al., 2010; Stiell et al., 2010; Beatch et al., 2017), particularly in comparison to other antiarrhythmic drugs, such as amiodarone (Camm et al., 2011), propafenone (Conde et al., 2013a), flecainide (Conde et al., 2013b), and ibutilide (Simon et al., 2017).

In Europe, per the 2012 ESC Guidelines on AF management, vernakalant received class I recommendation with level of evidence A for cardioversion of AF with structurally normal heart or minimal heart disease and class IIb recommendation with level of evidence B for cardioversion of patients with moderate structural heart disease (Camm et al., 2012). Unfortunately, despite its high conversion rate for recent-onset AF that would allow rapid and efficacious treatment in the emergency department to reduce cost of care, vernakalant has not been approved by the United States FDA due to lingering safety concerns, including hypotension, bradycardia (a common

adverse event), and the increased risk of serious adverse events ($\leq 2\%$) with usage in heart failure or post-acute coronary syndrome (Lindsay, 2011). The risk of vernakalant inducing sustained ventricular arrhythmias or torsades de pointes is low but may increase with concomitant use of Class I/III antiarrhythmic drugs (Beatch and Mangal, 2016; Akel and Lafferty, 2018). The opposing conclusions regarding vernakalant usage by the regulatory bodies from the two sides of the Atlantic is puzzling considering their examination of the same clinical evidence. Because of the United States' dominant position in the global marketplace, the FDA decision to withhold approval for vernakalant led sponsors of vernakalant to abandon further refinement pursuits for the drug.

Niferidil (RG-2)

Niferidil (RG-2) is a new class III antiarrhythmic drug, first introduced for human use in early 2010s. In patients, niferidil is highly effective for both persistent AF (85% conversion rate within 24 h) and recent-onset AF of less than 3-months duration (92% conversion rate) (Maykov et al., 2014). Because the study lacked randomization and placebo controls, more robust clinical trials are needed to demonstrate niferidil promising efficacy and safety profile in cardioversion of persistent AF. The ionic mechanisms responsible for its unique antiarrhythmic efficacy in human persistent AF have not been investigated. However, in guinea pigs, niferidil prolongs atrial action potential duration via I_{Kr} inhibition (Abramochkin et al., 2017). However, as demonstrated in mice, niferidil has off-target effects in the ventricular myocardium, where it also prolongs ventricular action potential duration in mice by inhibiting two other delayed rectifier K^+ current, I_{Kur} and the steady-state current (I_{ss}) (Abramochkin et al., 2015). It is unclear how probable off-target inhibition of human ventricular K^+ currents by niferidil affects its efficacy and safety profile as an antiarrhythmic drug for AF. Therefore, minimizing off-target effects to improve efficacy and safety is the motivation to improve atrial selectivity of new antiarrhythmic drugs for AF control.

New Atrial-Selective Atrial Fibrillation Antiarrhythmic Drugs (Vanoxerine, Antazoline, XEN-D0103, I_{K2P} Blockers)

The need for atrial selectivity galvanized efforts to repurpose existent drugs (vanoxerine, antazoline) and to develop novel antiarrhythmic drugs (XEN-D0103, I_{K2P} blockers) (Table 6).

Vanoxerine (GBR-12909)

Vanoxerine is a 1,4-dialkylpiperazine derivative, a potent and selective dopamine reuptake inhibitor originally designed to treat Parkinson's disease and depression due to its potent dopamine reuptake inhibition. Vanoxerine is a potent blocker of I_{Kr} , I_{CaL} , and I_{Na} in decreased order of potency. I_{CaL} and I_{Na} blocks are strongly frequency-dependent and can offset I_{Kr} block, such that vanoxerine does not prolong ventricular action potential duration or the QT interval, nor increase of the transmural dispersion of ventricular repolarization (Lacerda et al., 2010). These mechanisms likely explain why, unlike other class III

antiarrhythmic drugs, vanoxerine does not cause ventricular arrhythmias in animals (Matsumoto et al., 2010). Therefore, vanoxerine resembles amiodarone in therapeutic benefits with its multichannel block and repolarization uniformity, but thankfully not in amiodarone toxicity (Lacerda et al., 2010).

Subsequently, a randomized, double-blinded study confirmed vanoxerine superior efficacy to placebo (70% vs. 20%). However, the study was terminated early due to the occurrence of ventricular arrhythmias and torsades de pointes in the treatment group (Piccini et al., 2016). This concerning finding regarding vanoxerine safety profile was in contrast to an earlier phase 2B clinical trial, the *Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm* (COR-ART) trial, which found vanoxerine to have high conversion rate (84%), to be well tolerated, and to cause no ventricular arrhythmias (Dittrich et al., 2015). Clearly, larger studies are required to study the safety and efficacy of vanoxerine before definitive conclusions can be drawn. This may be a worthy endeavor if vanoxerine becomes a viable option for a pill-in-the-pocket approach for paroxysmal AF in structural heart disease where standard antiarrhythmic drugs are contraindicated.

Antazoline

Antazoline is a first-generation antihistamine with known antiarrhythmic properties and quinidine-like activities, first reported back in 1960s. Early data of the use of intravenous antazoline in AF cardioversion showed disappointing minimal efficacy (Gehring and Kehler, 1970). Since then, studies on antazoline have been sparse until recent renewed interest. Antazoline has been shown experimentally to reduce AF inducibility by increasing atrial APD, atrial ERP, atrial postrepolarization refractoriness, and interatrial conduction time. Inhibition of several ion currents, including both Na^+ and K^+ currents, presumably accounts for its antiarrhythmic effects (Frommeyer et al., 2017).

In the *Efficacy and Safety of Antazoline in the Rapid Cardioversion of Paroxysmal Atrial Fibrillation* (AnPAF) randomized clinical trial ($n = 74$ patients with paroxysmal AF) that antazoline could rapidly restore sinus rhythm (72.2% efficacy in the treatment group vs. 10.5% in the placebo group) and its only serious proarrhythmic effect was non-sustained sinus tachycardia in 5.6% of the treatment group (Maciag et al., 2017). A subsequent retrospective review of medical records from 450 Polish patients with short-duration AF, the *Cardioversion with Antazoline Mesylate* (CANT) study, demonstrated that antazoline represents an efficacious and safe method of pharmacological cardioversion with superior success rate compared to amiodarone and propafenone (Wybraniec et al., 2018). Thus, antazoline has emerged as a promising antiarrhythmic drug with cardioversion efficacy potentially surpassing amiodarone. However, additional randomized clinical trials are necessary to confirm this finding and to investigate its safety profile.

XEN-D0103/S66913

In the pipeline is XEN-D0103 (also known as S66913), a novel atrial-selective inhibitor of I_{Kur} carried by the $Kv1.5$ channel,

which expresses only in atria (Ford et al., 2016). A phase one study demonstrated that XEN-D-0103/S66913 may have promising therapeutic benefit for reducing AF burden because it prolonged the atrial action potential duration specifically without affecting the ventricles (Ford et al., 2016). However, a recent prospective single-center phase two double-blind, randomized, placebo-controlled, cross-over study ($n = 21$ patients with paroxysmal AF and implanted dual-chamber permanent pacemaker for conduction defects) found that although XEN-D0103 was well-tolerated, it did not reduce AF burden when used alone (Shunmugam et al., 2018).

A most recent randomized, double-blind, placebo-controlled trial, the *Double-blind, International study AssessinG efficacy of S 066913 in paRoxysmal Atrial Fibrillation*-IKur inhibitor (DIAGRAF-IKUR; $n = 58$ patients with paroxysmal AF being considered for ablation), confirmed prior findings that S66913 was safe but ineffective in reducing AF burden (Camm et al., 2019). However, due to the small sample sizes of these studies, further trials in larger patient samples are still needed to assess its efficacy in cardioversion and maintenance.

I_{K2P} Blockers (A293, Doxapram)

Another attractive target in the pipeline are atrial-selective inhibitors of I_{K2P} , a K^+ leak current carried by the most recently discovered K2P channels (Goldstein et al., 2001). Like other leak currents, I_{K2P} contributes to the resting membrane potential and controls myocyte excitability by shaping action potential amplitude, duration, and frequency. Several classic antiarrhythmic drugs, such as amiodarone, dronedarone, carvedilol, are non-selective I_{K2P} blockers; hence, the pressing need to develop selective I_{K2P} blockers for similar efficacy but improved safety.

The Two-pore-domain Weak Inward rectifying K^+ channel (TWIK)-related Acid-Sensitive K^+ channel-1 (TASK-1; $K_{2p3.1}$) is a member of the K2P channel family (Enyedi and Czirják, 2010). Because TASK-1 channels are abundant in human atria but not in ventricles (Heijman et al., 2017; Schmidt et al., 2017), TASK-1 channels regulate atrial action potential duration (Limberg et al., 2011). In chronic AF, but not in paroxysmal AF, atrial TASK-1-mediated $K_{2p3.1}$ current expression is upregulated and causes action potential shortening (Schmidt et al., 2015). In a preclinical trial with an AF pig model, inhibition of atrial-specific $K_{2p3.1}$ current using the TASK-1 channel blocker A293 reverses pathologic AF-related atrial action potential shortening and significantly prolongs atrial ERP without causing ventricular arrhythmias (Wiedmann et al., 2020). In another more recent pig preclinical trial, $K_{2p3.1}$ current inhibition by genetic ablation of TASK-1 channels using small interfering RNA (siRNA) prevents atrial electrical remodeling and suppresses AF (Schmidt et al., 2019). However, an important caveat is that in chronic-AF patients with heart failure due to left ventricular dysfunction, atrial $K_{2p3.1}$ expression is downregulated instead of upregulated, making it unlikely for I_{K2P} blockers to be an efficient anti-AF approach in patients with structurally remodeled atria (Schmidt et al., 2017).

These encouraging preclinical findings highlight the need to further assess in clinical trials the potential of atrial-selective

inhibition of I_{K2P} as a novel, promising mechanism-based strategy to treat AF. In fact, an ongoing clinical trial in Germany, the DOxapram Conversion TO Sinus rhythm study (DOCTOS Trial, EudraCT no. 2018-002979-17, $n = 40$ AF patients aged 18–64 years and $n = 40$ AF patients aged ≥ 65 years), is evaluating the efficacy and safety of doxapram, a potent atrial-selective I_{K2P} blocker, in cardioverting paroxysmal and persistent non-valvular AF to sinus rhythm within 6 h of intravenous administration. Doxapram, a known ventilator stimulant, blocks both TASK-1 and TASK-3 ($K_{2p9.1}$) channels. TASK-3, the closest relative of TASK-1, expresses prominently in human right auricles. Interestingly, human atrial TASK-1 and TASK-3 can form heterodimers (Rinné et al., 2015).

REDEFINING NATURAL HISTORY AND PATHOPHYSIOLOGICAL MECHANISMS

Paradigm Shift: From Three Distinct Atrial Fibrillation Temporal Patterns to One Progressive Fibro-Inflammatory “Atriomyopathy” Electrical Remodeling

An early breakthrough in AF pathophysiology came with the recognition of the pathogenic electrical remodeling process. In electrical remodeling, “AF begets AF”—that is AF leads to electrical remodeling of the atrial electrophysiology to facilitate further AF induction and maintenance (Wijffels et al., 1995)—such that by the time AF progresses to the permanent stage, attempts to restore sinus rhythm are doomed to fail and therefore should not be attempted. The main perturbations in AF electrical remodeling that lead to shortening of the atrial action potential duration and resultant shortening of atrial refractoriness include downregulation of I_{CaL} (Yue et al., 1997; Van Wagoner et al., 1999), upregulation of the inward rectifier current (I_{K1}) (Biliczki et al., 2019), upregulation of I_{SK} (Qi et al., 2014), and constitutive activation of I_{KACH} (Dobrev et al., 2001; Dobrev et al., 2005; Heijman et al., 2018). The main perturbations in AF electrical remodeling leading to aberrant Ca^{2+} handling and resultant increased likelihood of reentry (Liu et al., 2020) and delayed afterdepolarization (a well-known trigger of AF) include persistent diastolic ryanodine receptor (RyR2) leak due to both sustained sarcoplasmic reticulum Ca^{2+} overloading, Ca^{2+} /calmodulin kinase type II (CaMKII) activation, and upregulation of NCX (Nattel and Dobrev, 2012).

Structural Remodeling

The next breakthrough in AF pathophysiology came with the recognition of the pathogenic structural remodeling process. Fibrosis and inflammation were recognized as the hallmark of atrial structural remodeling in AF (Nattel, 2016; Yao et al., 2018). The knowledge that fibrosis and inflammation in AF correspond with disease severity and have prognostic value came with the technological advent of catheter ablation interventions for AF and late-gadolinium enhancement magnetic resonance imaging (LGE-MRI) to detect atrial fibrosis *in vivo*. LGE-MRI revealed

that atrial fibrosis severity determines AF ablation outcome, likelihood of AF recurrence, stroke risk, and significant sinus node dysfunction; therefore, assessment of atrial fibrosis can guide patient selection and ablation procedures (Akoum and Marrouche, 2014; McGann et al., 2014). Extensive atrial structural remodeling by fibrosis ($\geq 30\%$ LA wall enhancement) predicts poor response to catheter ablation therapy for AF (Marrouche et al., 2014; McGann et al., 2014). Importantly, even when ablation succeeds in restoring sinus rhythm, ablation causes additional inflammation and fibrosis that perpetuate the original electrical and structural remodeling caused by AF (Teh et al., 2012). After AF ablation, the atrial conduction slowing, the decrease in left atrial ejection fraction with or without atrial dilation, and the development of new ablation-induced inflammation and fibrosis (Okumura et al., 2011) indicate worsening atrial function and predict increased risk of AF recurrence (Marrouche et al., 2014; Kim et al., 2018; Kim et al., 2019). Marked atrial fibrosis and elevated levels of inflammatory markers in AF recurrences are evident both *in vivo* (Qu et al., 2009; Sonmez et al., 2014) and postmortem (Ito et al., 2013; Corradi et al., 2014). Collagen volume, activity of nuclear factor κ -light-chain-enhancer of activated B cells (NF- κ B, a crucial inflammatory signaling transcription factor) (Qu et al., 2009) and serum levels of fibro-inflammatory biomarkers are all elevated in persistent-AF (Sonmez et al., 2014) and post-ablation AF recurrence (Okumura et al., 2011). Importantly, this elevated fibro-inflammatory state positively correlates with left atrial dilatation, an index of atrial structural (Sonmez et al., 2014).

Natural History

A breakthrough in AF natural history came with the realization of the prognostic value of the AF burden (duration and frequency of AF episodes) on disease progression. The knowledge of this longitudinal evolution of AF prompted the American College of Cardiology (ACC), American Heart Association (AHA), and ESC to classify AF based on temporal rhythm patterns into paroxysmal, persistent, and permanent and to recommend indications for therapeutic interventions based on AF class (Fuster et al., 2006; Jahangir et al., 2007; Ogawa et al., 2018).

Progressive “Atrio-myopathy”

A most significant breakthrough in AF natural history and pathophysiology came with the appreciation that atrial electrical remodeling is intertwined with atrial structural remodeling (Li et al., 1999; Nattel et al., 2008) in a regenerative positive feedback loop that amplifies the pathophysiology of the initial AF episodes. We coined the term “atriomyopathy” to describe the ultimate consequence of the synergy of these two relentless AF pathogenic remodeling processes for the atrial myocardium. The progressive nature of AF atrio-myopathy implies a critical need for early rhythm-control therapy in AF because timing matters in preventing or delaying the progression of AF atrio-myopathy. This paradigm-shifting therapeutic strategy is most recently validated by the *Early Treatment of Atrial Fibrillation for Stroke Prevention Trial* (EAST-AFNET 4), an international, randomized, open, blinded-outcome-assessment clinical trial (Kirchhof et al., 2020). In fact, the most recently published 2020

AF guidelines mark a revolutionizing paradigm shift in management strategies because the pressing need for primary prevention to thwart AF atrio-myopathy onset is emphasized for the first time (Hindricks et al., 2020).

REDEFINING THERAPEUTIC GOALS

Paradigm Shift: The Need for a Mechanism-Based Multipronged Strategy

To date, AF has been treated for rate control by antiarrhythmic drugs and for rhythm control by either antiarrhythmic drugs or invasive ablation. While the invasive Cox-maze and catheter ablation have evolved over the last three-and-a-half and 2 decades, respectively, antiarrhythmic drugs for AF have evolved over three-and-a-half centuries. Yet, our expectations for an efficacious and safe AF management strategy have not been met. Over that same time, thanks to basic and clinical research, our understanding of AF pathophysiology has also evolved from the assumption of AF as a static disease to the appreciation of AF as a progressive fibro-inflammatory atrio-myopathy driven by a relentless positive feedback loop between electrical and structural remodeling. Therefore, our AF management focus also needs to evolve from a pure curative intent to incorporate preventive intent. Importantly, our AF management strategy also needs to evolve from the historical “one-fits-all” approach to a modern mechanism-based multipronged strategy to target both pathogenic electrical and structural remodeling processes (Figure 1).

Targeting Electrical Remodeling

To prevent or forestall pathogenic electrical remodeling with efficacy and safety, basic research has revealed at least three novel aspects to focus the development of antiarrhythmic drugs: atrial selectivity, multiple-ion-channel blockade, and Ca^{2+} -mishandling targets. Novel potential ionic current targets include the currents carried by K^+ channels with atrial-predominant expression, such as I_{Kur} , I_{Kr} , I_{SK} , and I_{KACH} . Ca^{2+} mishandling also offers promising targets for stabilizers of RyR2, modulators of the sarcoplasmic reticulum Ca^{2+} -ATPase 2a (SERCA2a), and inhibitors of NCX, CaMKII, and Ca^{2+} -dependent protease calpain.

Targeting Structural Remodeling

Unlike electrical remodeling, which offers opportunities for reversibility, to date structural remodeling has not been meaningfully reversed once established. Therefore, prevention is the best approach to target pathogenic structural remodeling (Benjamin et al., 2009; Savelieva et al., 2011a; Savelieva et al., 2011b). Clinical targeting of modifiable AF risk factors such as diabetes, hypertension, obesity, and obstructive sleep apnea should be early and aggressive. Statins, and anti-inflammatory drugs targeting cytokines (IL-1 β , IL-6, and TNF- α) and the renin-angiotensin-aldosterone system (RAAS) have been tried as potential therapies to forestall the progression of inflammation and fibrosis (Savelieva et al., 2011a; Savelieva et al., 2011b;




FIGURE 1 | Atrial fibrillation natural history, pathophysiology, and therapeutic strategy.

Chaugai et al., 2016). Unfortunately, clinical success is still lacking, consistent with the irreversibility of structural remodeling.

Targeting Both Electrical and Structural Remodeling

Other promising areas of active research in modulation of microRNA (miRNA) expression and of the autonomic nervous system focus on mechanisms that target both electrical and structural remodeling simultaneously. Basic and clinical science have recently discovered the central signaling role of miRNAs in AF pathogenesis (Luo et al., 2015; Shen et al., 2020). Multiple dysregulated miRNAs, including miR-1, miR-26, miR-

106b-25, miR-208a, miR-328, and miR-499, contribute to AF electrical remodeling (Lu et al., 2010; Ling et al., 2013; Luo et al., 2013; Soeki et al., 2016). These miRNAs target and dysregulate the expression of genes encoding critical atrial K⁺ and Ca²⁺ ion channels to cause shortening atrial action potential duration and effective refractory period to favor reentry for AF maintenance. Other multiple dysregulated miRNAs, including miR-21, miR-26, miR-29, miR-30, miR-133, and miR-590, contribute to AF profibrotic structural remodeling (Dawson et al., 2013; Cheng et al., 2019; Sieweke et al., 2020). Therefore, modulating miRNAs has the potential of an innovative AF management strategy of important therapeutic, diagnostic, and prognostic values.

Neural modulation promises another frontier in AF rate and rhythm control given the prominent role of neural remodeling in AF initiation and maintenance (Chen et al., 2014). Autonomic nervous system activation of either limb or both limbs simultaneously can promote AF (Coumel, 1993). Neural remodeling perpetuates AF by engaging a positive feedback loop with adverse atrial electrical and structural remodeling. Sympathetic stimulation induces adrenergic AF (Lu et al., 2008) and facilitates cholinergic AF induction (Hashimoto et al., 1968; Sharifov et al., 2004). Sympathetic stimulation induces adverse atrial neural remodeling by heterogeneous sympathetic hyperinnervation and extensive nerve sprouting (Jayachandran et al., 2000; Chang et al., 2001). Sympathetic stimulation induces adverse atrial electrical remodeling by causing cellular Ca^{2+} overload and mishandling, activating NCX forward-mode and CaMKII, thereby promoting the emergence of AF triggers and shifting of pacemaker activity to ultrarapid-firing ectopic atrial sites (Geesbreght and Randall, 1971). Sympathetic stimulation induces adverse structural remodeling by causing myocyte apoptosis and myocardial fibrosis. Hence, to prevent or reverse AF electrical and structural remodeling, suppression of sympathetic outflow has been investigated using antiadrenergic drugs, renal sympathetic denervation (Wang et al., 2013), or ablation of atrial ganglionated plexi. Sympathetic suppression may reduce AF burden and inducibility and improve the success of pulmonary vein isolation (Katritsis et al., 2011), but success has proved inconsistent.

More curious are the paradoxical contributions of vagal stimulation to both AF pathogenesis and AF therapy (Chen et al., 2014). Vagal stimulation induces cholinergic AF (Hashimoto et al., 1968; Levitt et al., 1976a), also by causing adverse electrical and structural remodeling. Vagal stimulation induces adverse atrial electrical remodeling by heterogeneous shortening of atrial ERP (Liu and Nattel, 1997) and increasing dispersion of atrial refractoriness (Alessi et al., 1958), heterogeneous shortening of atrial action potential duration and increasing dispersion of atrial repolarization as well as increasing interatrial dyssynchrony (Ninomiya, 1966). Vagal stimulation induces profibrotic cardiac structural remodeling. For example, following T₅ spinal cord transection, parasympathetic hyperinnervation causes dilation of left ventricular chamber, thinning of myocardial wall, and increased collagen content (Lujan et al., 2014). Therefore, it comes as no surprise that suppression of vagal stimulation by anticholinergic drugs or vagal denervation may improve the efficacy of pulmonary vein isolation to prevent AF recurrence (Chen and Tan, 2007) and reduces AF inducibility (Elvan et al., 1995). Likewise, suppression of vagal stimulation by ablation of pulmonary vein ganglionated plexi may increase the success of pulmonary vein isolation by mitigating vagally-induced shortening of atrial ERP (Lemola et al., 2008). Interestingly, botulinum toxin, known to inhibit vesicular release of intracellular acetylcholine from presynaptic neurons, presents a novel neuromodulation approach in AF therapeutics by simultaneous sympathovagal suppression. Recently, two prospective, double-blind study of patients with paroxysmal AF undergoing coronary artery bypass grafting, found that botulinum toxin injected into the epicardial fat pad suppressed

AF both early post-operatively and, surprisingly, long-term during 1-year (Pokushalov et al., 2015) and 3-years follow up (Romanov et al., 2019). The unexpected salutary long-term antiarrhythmic effects of botulinum toxin were attributed to its suppression of the ganglionated plexi activity (Pokushalov et al., 2015).

Thus, it may seem shockingly heretical at first to suggest vagal stimulation as a promising candidate for the new frontier in AF therapeutics. Yet, it has long been recognized that digoxin controls ventricular response during AF by vagal stimulation of the atrioventricular node. Likewise, direct electrical stimulation of the right inferior ganglionated plexus may slow ventricular response in postoperative AF by slowing atrioventricular node conduction. However, the emerging paradigm of AF neuromodulation by vagal stimulation relies on another mechanism to suppress AF, namely by preventing or reversing atrial electrical and structural remodeling. Not all vagal stimulation is arrhythmogenic; the proarrhythmic vs. antiarrhythmic effects are dictated by the strength and duration of vagal stimulation and the complex but poorly understood interactions between the extrinsic and intrinsic cardiac autonomic nervous system. For example, in a dog model of tachypacing-induced AF, strong vagal nerve stimulation that slows the sinus rate by at least 60% facilitates AF inducibility, but moderate vagal nerve stimulation that slows the sinus rate by only 10–30% does not shorten atrial ERP or affect AF inducibility (Takei et al., 2001; Zhang et al., 2009a). Low-level stimulation of the extrinsic cardiac autonomic nervous system can suppress AF by inhibiting the autonomic outflow of intrinsic cardiac autonomic nervous system (Zhang et al., 2009c; Shen et al., 2011; Yu et al., 2011). In fact, low-level vagus nerve stimulation (LLVS) can suppress tachypacing-induced adrenergic AF as well as cholinergic-induced AF by mitigating neural remodeling by the intrinsic cardiac autonomic nervous system, thereby preventing and reversing adverse atrial electrical and structural remodeling (Sheng et al., 2011; Kusunose et al., 2014; Beaumont et al., 2015). LLVS suppresses post-operative AF and attenuates inflammation (decreased serum TNF- α and IL-6) (Zhang et al., 2009b; Rossi et al., 2012; Stavrakis et al., 2017). Likewise, in dogs and humans, transcutaneous low-level tragus electrical stimulation (LLTS) suppresses AF and attendant generation of inflammatory cytokines in patients with paroxysmal AF (Stavrakis et al., 2015). The *Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation* (TREAT-AF), a sham-controlled, double-blind, randomized clinical trial just completed in April 2020, found that intermittent LLTS lowers the AF burden in patients with paroxysmal AF compared to sham control stimulation (Stavrakis et al., 2020).

From these exciting experimental and clinical findings regarding neuromodulation as AF treatment, we learn at least two important lessons. First, to improve efficacy and safety, future antiarrhythmic drugs should have not only atrial selectivity but also dual adrenergic and cholinergic activities (like amiodarone) instead of only a single activity. Second, discrepancies in findings and inconsistencies in success surrounding the use of neuromodulation for AF control

highlight the complexity of the dynamic influences of the cardiac autonomic nervous system on AF pathogenesis and the need for future research to guide appropriate identification of patients who would most benefit from neuromodulation for AF prevention or AF control based on individual variability in autonomic influences on existing cardiac structural and electrical remodeling.

Paradigm Shift: From Drug-Centricity to Patient-Centricity

In summary, as the progressive nature of AF atriomypopathy and the synergy of the two pathogenic remodeling processes in AF becomes clearer, identifying novel therapeutic targets and strategies will progress. We may also become better at considering individual variabilities in genes, environment, and lifestyle to bring precision medicine to AF therapeutics. The hope is to shift the overarching AF therapeutic paradigm from drug-centricity to patient-centricity.

AUTHOR CONTRIBUTIONS

MG and AL performed literature search and assisted with manuscript preparation. TN conceived the review, performed literature search, and prepared the manuscript. All authors contributed to manuscript revision, approved the submitted version, and agreed to be accountable for all aspects of the work.

REFERENCES

- Abramochkin, D. V., Kuzmin, V. S., and Rosenshtraukh, L. V. (2015). Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 388, 1105–1112. doi:10.1007/s00210-015-1146-x
- Abramochkin, D. V., Kuzmin, V. S., and Rosenshtraukh, L. V. (2017). A new class III antiarrhythmic drug niferidil prolongs action potentials in Guinea pig atrial myocardium via inhibition of rapid delayed rectifier. *Cardiovasc. Drugs Ther.* 31, 525–533. doi:10.1007/s10557-017-6762-x
- Akel, T., and Lafferty, J. (2018). Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: a meta-analysis. *Ann. Noninvasive Electrocardiol.* 23, e12508. doi:10.1111/anec.12505
- Akoum, N., and Marrouche, N. (2014). Assessment and impact of cardiac fibrosis on atrial fibrillation. *Curr. Cardiol. Rep.* 16, 518. doi:10.1007/s11886-014-0518-z
- Alessi, R., Nusynowitz, M., Abildskov, J. A., and Moe, G. K. (1958). Nonuniform distribution of vagal effects on the atrial refractory period. *Am. J. Physiol. Legacy Content* 194, 406–410. doi:10.1152/ajplegacy.1958.194.2.406
- Anderson, J. L., Gilbert, E. M., Alpert, B. L., Henthorn, R. W., Waldo, A. L., Bhandari, A. K., et al. (1989). Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. *Circulation* 80, 1557–1570. doi:10.1161/01.cir.80.6.1557
- Anderson, J. L., Platia, E. V., Hallstrom, A., Henthorn, R. W., Buckingham, T. A., Carlson, M. D., et al. (1994). Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). *Circulation* 90, 2843–2852. doi:10.1161/01.cir.90.6.2843

FUNDING

This work was supported by the National Institutes of Health R01 HL141452 to TN.

CLINICAL TRIAL ACRONYMS

AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management; AnPAF, Efficacy and Safety of Antazoline in the Rapid Cardioversion of Paroxysmal Atrial Fibrillation; CABANA, Catheter Ablation vs. Antiarrhythmic Drug Therapy for AF; CAFÉ-II, Controlled Study of Rate vs. Rhythm Control in Patients with Chronic AF and Heart Failure; CANT, Cardioversion with Antazoline Mesylate; CAST, Cardiac Arrhythmia Suppression Trial; CASTLE-AF, Catheter Ablation vs. Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation; COR-AT, Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm; DIAGRAF-IKUR, Double-blind, International study Assessing efficacy of S 066913 in paroxysmal Atrial Fibrillation-IKUR inhibitor; DOCTOS, DOxapram Conversion TO Sinus rhythm study; EAST-AFNET 4, Early Treatment of Atrial Fibrillation for Stroke Prevention Trial; SAFIRE-D, Symptomatic AF Investigative Research on Dofetilide; TREAT-AF, Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation.

- Antzelevitch, C., Burashnikov, A., Sicouri, S., and Belardinelli, L. (2011). Electrophysiologic basis for the antiarrhythmic actions of ranolazine. *Heart Rhythm* 8, 1281–1290. doi:10.1016/j.hrthm.2011.03.045
- Askey, J. M. (1946). Quinidine in the treatment of auricular fibrillation in association with congestive failure. *Ann. Intern. Med.* 24, 371–384. doi:10.7326/0003-4819-24-3-371
- Banerjee, A., Allan, V., Denaxas, S., Shah, A., Kotecha, D., Lambiase, P. D., et al. (2019). Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. *Europace* 21 (12), 1776–1784. doi:10.1093/europace/euz323
- Beatch, G. N., Bhirangi, K., Juul-Moller, S., and Rustige, J. (2017). Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in the asia-pacific region. *J. Cardiovasc. Pharmacol.* 69, 86–92. doi:10.1097/fjc.0000000000000445
- Beatch, G. N., and Mangal, B. (2016). Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial. *BMC Cardiovasc. Disord.* 16, 113. doi:10.1186/s12872-016-0289-0
- Beaumont, E., Southerland, E. M., Hardwick, J. C., Wright, G. L., Ryan, S., Li, Y., et al. (2015). Vagus nerve stimulation mitigates intrinsic cardiac neuronal and adverse myocyte remodeling postmyocardial infarction. *Am. J. Physiol. Heart Circ. Physiol.* 309, H1198–H1206. doi:10.1152/ajpheart.00393.2015
- Bellandi, F., Simonetti, I., Leoncini, M., Frascarelli, F., Giovannini, T., Maioli, M., et al. (2001). Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. *Am. J. Cardiol.* 88, 640–645. doi:10.1016/s0002-9149(01)01806-9
- Benjamin, E. J., Chen, P.-S., Bild, D. E., Mascette, A. M., Albert, C. M., Alonso, A., et al. (2009). Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. *Circulation* 119, 606–618. doi:10.1161/circulationaha.108.825380
- Benjamin, E. J., Levy, D., Vaziri, S. M., D'agostino, R. B., Belanger, A. J., and Wolf, P. A. (1994). Independent risk factors for atrial fibrillation in a population-

- based cohort. The Framingham Heart Study. *JAMA* 271, 840–844. doi:10.1001/jama.271.11.840
- Biliczki, P., Boon, R. A., Girmatsion, Z., Bukowska, A., Ördög, B., Kaess, B. M., et al. (2019). Age-related regulation and region-specific distribution of ion channel subunits promoting atrial fibrillation in human left and right atria. *Europace* 21, 1261–1269. doi:10.1093/europace/euz135
- Burashnikov, A., and Antzelevitch, C. (2009). Atrial-selective sodium channel block for the treatment of atrial fibrillation. *Expert Opin. Emerg. Drugs* 14, 233–249. doi:10.1517/14728210902997939
- Burashnikov, A., Di Diego, J. M., Zygmunt, A. C., Belardinelli, L., and Antzelevitch, C. (2007). Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. *Circulation* 116, 1449–1457. doi:10.1161/circulationaha.107.704890
- Burstein, B., and Nattel, S. (2008). Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. *J. Am. Coll. Cardiol.* 51, 802–809. doi:10.1016/j.jacc.2007.09.064
- Caliskan, E., Sahin, A., Yilmaz, M., Seifert, B., Hinzpeter, R., Alkadh, H., et al. (2018). Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. *Europace* 20, e105–e114. doi:10.1093/europace/eux211
- Calkins, H., Brugada, J., Packer, D. L., Cappato, R., Chen, S.-A., Crijns, H. J. G., et al. (2007). HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. *Heart Rhythm* 4, 816–861. doi:10.1016/j.hrthm.2007.04.005
- Calkins, H., Hindricks, G., Cappato, R., Kim, Y.-H., Saad, E. B., Aguinaga, L., et al. (2018). 2017 HRS/EHRA/ECAS/APHS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. *Europace* 20, 157–208. doi:10.1093/europace/eux275
- Camm, A. J., Capucci, A., Hohnloser, S. H., Torp-Pedersen, C., Van Gelder, I. C., Mangal, B., et al. (2011). A randomized active-controlled trial assessing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. *J. Am. Coll. Cardiol.* 57, 313–321. doi:10.1016/j.jacc.2010.07.046
- Camm, A. J., Dorian, P., Hohnloser, S. H., Kowey, P. R., Tyl, B., Ni, Y., et al. (2019). A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. *Eur. Heart J. Cardiovasc. Pharmacother.* 5, 21–28. doi:10.1093/ehjcvp/pyy022
- Camm, A. J., Kirchhof, P., Camm, A. J., Kirchhof, P., Lip, G. Y., Schotten, U., et al. (2010). Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). *Eur. Heart J.* 31, 2369–2429. doi:10.1093/eurheartj/ehq278
- Camm, A. J., Lip, G. Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., et al. (2012). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation—an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. *Europace* 14, 1385–1413. doi:10.1093/europace/eus305
- Chang, C.-M., Wu, T.-J., Zhou, S., Doshi, R. N., Lee, M.-H., Ohara, T., et al. (2001). Nerve sprouting and sympathetic hyperinnervation in a canine model of atrial fibrillation produced by prolonged right atrial pacing. *Circulation* 103, 22–25. doi:10.1161/01.cir.103.1.22
- Chaugai, S., Meng, W. Y., and Ali Sepehry, A. (2016). Effects of RAAS blockers on atrial fibrillation prophylaxis. *J. Cardiovasc. Pharmacol. Therapeut.* 21, 388–404. doi:10.1177/1074248415619490
- Chen, P.-S., Chen, L. S., Fishbein, M. C., Lin, S.-F., and Nattel, S. (2014). Role of the autonomic nervous system in atrial fibrillation. *Circ. Res.* 114, 1500–1515. doi:10.1161/circresaha.114.303772
- Chen, P.-S., and Tan, A. Y. (2007). Autonomic nerve activity and atrial fibrillation. *Heart Rhythm* 4, S61–S64. doi:10.1016/j.hrthm.2006.12.006
- Cheng, W. L., Kao, Y. H., Chao, T. F., Lin, Y. K., Chen, S. A., and Chen, Y. J. (2019). MicroRNA-133 suppresses ZFH3-dependent atrial remodeling and arrhythmia. *Acta Physiol.* 227, e13322. doi:10.1111/apha.13322
- Colilla, S., Crow, A., Petkun, W., Singer, D. E., Simon, T., and Liu, X. (2013). Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. *Am. J. Cardiol.* 112, 1142–1147. doi:10.1016/j.amjcard.2013.05.063
- Conde, D., Costabel, J. P., Aragon, M., Lambardi, F., Klein, A., Corrales Barbosa, A., et al. (2013a). Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation. *Cardiovasc Ther* 31, 377–380. doi:10.1111/1755-5922.12036
- Conde, D., Costabel, J. P., Caro, M., Ferro, A., Lambardi, F., Corrales Barboza, A., et al. (2013b). Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. *Int. J. Cardiol.* 168, 2423–2425. doi:10.1016/j.ijcard.2013.02.006
- Connolly, S. J., Camm, A. J., Halperin, J. L., Joyner, C., Alings, M., Amerena, J., et al. (2011). Dronedarone in high-risk permanent atrial fibrillation. *N. Engl. J. Med.* 365, 2268–2276. doi:10.1056/nejmoa1109867
- Corley, S. D., Epstein, A. E., Dimarco, J. P., Domanski, M. J., Geller, N., Greene, H. L., et al. (2004). Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. *Circulation* 109, 1509–1513. doi:10.1161/01.CIR.0000121736.16643.11
- Corradi, D., Callegari, S., Manotti, L., Ferrara, D., Goldoni, M., Alinovi, R., et al. (2014). Persistent lone atrial fibrillation: clinicopathologic study of 19 cases. *Heart Rhythm* 11, 1250–1258. doi:10.1016/j.hrthm.2014.02.008
- Coumel, P. (1993). Cardiac arrhythmias and the autonomic nervous system. *J. Cardiovasc. Electrophysiol.* 4, 338–355. doi:10.1111/j.1540-8167.1993.tb01235.x
- Dawson, K., Wakili, R., Ördög, B., Clauss, S., Chen, Y., Iwasaki, Y., et al. (2013). MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. *Circulation* 127, 1466–1475. doi:10.1161/circulationaha.112.001207
- De Vecchis, R., Ariano, C., Giasi, A., and Cioppa, C. (2018). Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. *Minerva Cardioangiol.* 66, 349–359. doi:10.23736/s0026-4725.17.04382-1
- Di Biase, L., Burkhardt, J. D., Mohanty, P., Sanchez, J., Mohanty, S., Horton, R., et al. (2010). Left atrial appendage: an underrecognized trigger site of atrial fibrillation. *Circulation* 122, 109–118. doi:10.1161/circulationaha.109.928903
- Dittrich, H. C., Feld, G. K., Bahnson, T. D., Camm, A. J., Golitsyn, S., Katz, A., et al. (2015). COR-ART: a multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. *Heart Rhythm* 12, 1105–1112. doi:10.1016/j.hrthm.2015.02.014
- Dobrev, D., Friedrich, A., Voigt, N., Jost, N., Wettwer, E., Christ, T., et al. (2005). The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. *Circulation* 112, 3697–3706. doi:10.1161/circulationaha.105.575332
- Dobrev, D., Graf, E., Wettwer, E., Himmel, H. M., Hála, O., Doerfel, C., et al. (2001). Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. *Circulation* 104, 2551–2557. doi:10.1161/hc4601.099466
- Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., et al. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. *N. Engl. J. Med.* 324, 781–788. doi:10.1056/nejm199103213241201
- Einthoven, W. (1906). Le telecardiogramme. *Arch. Int. Physiol.* 4, 132–164
- Eldstrom, J., Wang, Z., Xu, H., Pourrier, M., Ezrin, A., Gibson, K., et al. (2007). The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. *Mol. Pharmacol.* 72, 1522–1534. doi:10.1124/mol.107.039388
- Ellenbogen, K. A. (2007). Pacing therapy for prevention of atrial fibrillation. *Heart Rhythm* 4, S84–S87. doi:10.1016/j.hrthm.2006.12.005
- Ellis, C. R., Aznaurov, S. G., Patel, N. J., Williams, J. R., Sandler, K. L., Hoff, S. J., et al. (2017). Angiographic efficacy of the atriclip left atrial appendage exclusion device placed by minimally invasive thorascopic approach. *JACC Clinical Electrophysiol.* 3, 1356–1365. doi:10.1016/j.jacep.2017.03.008
- Elvan, A., Pride, H. P., Eble, J. N., and Zipes, D. P. (1995). Radiofrequency catheter ablation of the atria reduces inducibility and duration of atrial fibrillation in dogs. *Circulation* 91, 2235–2244. doi:10.1161/01.cir.91.8.2235
- Enyedi, P., and Czizrák, G. (2010). Molecular background of leak K+ currents: two-pore domain potassium channels. *Physiol. Rev.* 90, 559–605. doi:10.1152/physrev.00029.2009

- Fedida, D., Orth, P. M. R., Chen, J. Y. C., Lin, S., Plouvier, B., Jung, G., et al. (2005). The mechanism of atrial antiarrhythmic action of RSD1235. *J. Cardiovasc. Electrophysiol.* 16, 1227–1238. doi:10.1111/j.1540-8167.2005.50028.x
- Fedida, D., Orth, P. M. R., Hesketh, J. C., and Ezrin, A. M. (2006). The role of late I_{Na} and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. *J. Cardiovasc. Electrophysiol.* 17 (Suppl. 1), S71–S78. doi:10.1111/j.1540-8167.2006.00386.x
- Fetsch, T., Bauer, P., Engberding, R., Koch, H. P., Luki, J., Meinertz, T., et al. (2004). Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. *Eur. Heart J.* 25, 1385–1394. doi:10.1016/j.ehj.2004.04.015
- Ford, J., Milnes, J., El Haou, S., Wettwer, E., Loose, S., Matschke, K., et al. (2016). The positive frequency-dependent electrophysiological effects of the IK_{ur} inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation. *Heart Rhythm* 13, 555–564. doi:10.1016/j.hrthm.2015.10.003
- Freemantle, N., Lafuente-Lafuente, C., Mitchell, S., Eckert, L., and Reynolds, M. (2011). Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. *Europace* 13, 329–345. doi:10.1093/europace/euq450
- Fromm, C., Suau, S. J., Cohen, V., Likourezos, A., Jellinek-Cohen, S., Rose, J., et al. (2015). Diltiazem vs. Metoprolol in the management of atrial fibrillation or flutter with rapid ventricular rate in the emergency department. *J. Emerg. Med.* 49, 175–182. doi:10.1016/j.jemermed.2015.01.014
- Frommeyer, G., Sterneberg, M., Dechering, D. G., Kaese, S., Bogeholz, N., Pott, C., et al. (2017). Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: first experimental insights into a novel antiarrhythmic agent. *Cardiovasc. Ther.* 35 (2), e12244. doi:10.1111/1755-5922.12244
- Fuster, V., Rydén, L. E., Asinger, R. W., Cannom, D. S., Crijns, H. J., Frye, R. L., et al. (2011). ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation). *J. Am. Coll. Cardiol.* 38, 1231–1265. doi:10.1016/s0735-1097(01)01587-x
- Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). *J. Am. Coll. Cardiol.* 48, 854–906. doi:10.1016/j.jacc.2006.07.009
- Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2011). 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 123, e269–367. doi:10.1161/cir.0b013e318214876d
- Geesbreght, J., and Randall, W. (1971). Area localization of shifting cardiac pacemakers during sympathetic stimulation. *American J. Physiol. Legacy Content* 220, 1522–1527. doi:10.1152/ajplegacy.1971.220.5.1522
- Gehring, D. A., and Kehler, J. G. (1970). Conversion of atrial fibrillation with antazoline hydrochloride (Arithmin). *Angiology* 21, 11–17. doi:10.1177/000331977002100104
- Geller, J., Reek, S., Timmermans, C., Kayser, T., Tse, H. F., Wolpert, C., et al. (2003). Treatment of atrial fibrillation with an implantable atrial defibrillator - long term results. *Eur. Heart J.* 24, 2083–2089. doi:10.1016/j.ehj.2003.09.033
- Goldstein, S. A. N., Bockenbauer, D., O'Kelly, I., and Zilberberg, N. (2001). Potassium leak channels and the KCNK family of two-P-domain subunits. *Nat. Rev. Neurosci.* 2, 175–184. doi:10.1038/35058574
- Goodman, D. J., Rossen, R. M., Cannom, D. S., Rider, A. K., and Harrison, D. C. (1975). Effect of digoxin on atioventricular conduction. Studies in patients with and without cardiac autonomic innervation. *Circulation* 51, 251–256. doi:10.1161/01.cir.51.2.251
- Greiser, M., Lederer, W. J., and Schotten, U. (2011). Alterations of atrial Ca²⁺ handling as cause and consequence of atrial fibrillation. *Cardiovasc. Res.* 89, 722–733. doi:10.1093/cvr/cvq389
- Haïssaguerre, M., Jaïs, P., Shah, D. C., Takahashi, A., Hocini, M., Quiniou, G., et al. (1998). Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N. Engl. J. Med.* 339, 659–666. doi:10.1056/nejm199809033391003
- Hale, S. L., Leeka, J. A., and Kloner, R. A. (2006). Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. *J. Pharmacol. Exp. Therapeut.* 318, 418–423. doi:10.1124/jpet.106.103242
- Hale, S. L., Shryock, J. C., Belardinelli, L., Sweeney, M., and Kloner, R. A. (2008). Late sodium current inhibition as a new cardioprotective approach. *J. Mol. Cell. Cardiol.* 44, 954–967. doi:10.1016/j.yjmcc.2008.03.019
- Härtel, G., Louhija, A., and Kontinen, A. (1974). Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. *Clin. Pharmacol. Ther.* 15, 551–555. doi:10.1002/cpt1974156551
- Hashimoto, K., Chiba, S., Tanaka, S., Hirata, M., and Suzuki, Y. (1968). Adrenergic mechanism participating in induction of atrial fibrillation by ACh. *American J. Physiol. Legacy Content* 215, 1183–1191. doi:10.1152/ajplegacy.1968.215.5.1183
- Heijman, J., Ghezelbash, S., and Dobrev, D. (2017). Investigational antiarrhythmic agents: promising drugs in early clinical development. *Expert Opin. Invest. Drugs* 26, 897–907. doi:10.1080/13543784.2017.1353601
- Heijman, J., Kirchner, D., Kunze, F., Chrétien, E. M., Michel-Reher, M. B., Voigt, N., et al. (2018). Muscarinic type-1 receptors contribute to I_{K,ACh} in human atrial cardiomyocytes and are upregulated in patients with chronic atrial fibrillation. *Int. J. Cardiol.* 255, 61–68. doi:10.1016/j.ijcard.2017.12.050
- Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., et al. (2020). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). *Eur. Heart J.* [Epub ahead of print]. doi:10.1093/eurheartj/ehaa612
- Hocini, M., Shah, A. J., Nault, I., Sanders, P., Wright, M., Narayan, S. M., et al. (2011). Localized reentry within the left atrial appendage: arrhythmogenic role in patients undergoing ablation of persistent atrial fibrillation. *Heart Rhythm* 8, 1853–1861. doi:10.1016/j.hrthm.2011.07.013
- Hohnloser, S. H., Crijns, H. J. G. M., Van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C., et al. (2009). Effect of dronedarone on cardiovascular events in atrial fibrillation. *N. Engl. J. Med.* 360, 668–678. doi:10.1056/nejmoa0803778
- Hu, W.-S., and Lin, C.-L. (2019). Risk of atrial fibrillation in patients with congenital heart disease: results of a propensity score-matched, nationwide cohort study. *J. Atheroscler. Thromb.* 26, 670–677. doi:10.5551/jat.48835
- Ito, K., Date, T., Ikegami, M., Hongo, K., Fujisaki, M., Katoh, D., et al. (2013). An immunohistochemical analysis of tissue thrombin expression in the human atria. *PLoS One* 8, e65817. doi:10.1371/journal.pone.0065817
- Jahangir, A., Lee, V., Friedman, P. A., Trusty, J. M., Hodge, D. O., Kopecky, S. L., et al. (2007). Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. *Circulation* 115, 3050–3056. doi:10.1161/circulationaha.106.644484
- January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Jr., et al. (2014). 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *J. Am. Coll. Cardiol.* 64, e1–e76. doi:10.1016/j.jacc.2014.03.022
- January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Jr., et al. (2019). 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. *J. Am. Coll. Cardiol.* 74, 104–132. doi:10.1016/j.jacc.2019.01.011
- Jayachandran, J. V., Sih, H. J., Winkle, W., Zipes, D. P., Hutchins, G. D., and Olgin, J. E. (2000). Atrial fibrillation produced by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation. *Circulation* 101, 1185–1191. doi:10.1161/01.cir.101.10.1185
- Katritsis, D. G., Gazizoglou, E., Zografos, T., Pokushalov, E., Po, S. S., and Camm, A. J. (2011). Rapid pulmonary vein isolation combined with autonomic ganglia modification: a randomized study. *Heart Rhythm* 8, 672–678. doi:10.1016/j.hrthm.2010.12.047

- Khan, I. A., Mehta, N. J., and Gowda, R. M. (2003). Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. *Int. J. Cardiol.* 89, 239–248. doi:10.1016/s0167-5273(02)00477-1
- Kim, M. H., Johnston, S. S., Chu, B.-C., Dalal, M. R., and Schulman, K. L. (2011). Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. *Circ. Cardiovasc. Qual. Outcomes* 4, 313–320. doi:10.1161/circoutcomes.110.958165
- Kim, Y. G., Choi, J. I., Boo, K. Y., Kim, D. Y., Oh, S. K., Park, H. S., et al. (2019). Clinical and echocardiographic risk factors predict late recurrence after radiofrequency catheter ablation of atrial fibrillation. *Sci. Rep.* 9, 6890. doi:10.1038/s41598-019-43283-7
- Kim, Y. G., Shim, J., Oh, S. K., Park, H. S., Lee, K. N., Hwang, S. H., et al. (2018). Different responses of left atrium and left atrial appendage to radiofrequency catheter ablation of atrial fibrillation: a follow up MRI study. *Sci. Rep.* 8, 7871. doi:10.1038/s41598-018-26212-y
- Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., et al. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Kardiologia Polska* 18, 1609–1678. doi:10.1093/europace/euw295
- Kirchhof, P., Camm, A. J., Goette, A., Brandes, A., Eckardt, L., Elvan, A., et al. (2020). Early rhythm-control therapy in patients with atrial fibrillation. *N. Engl. J. Med.* 383 (14), 1305–1316. doi:10.1056/NEJMoa2019422
- Koskinas, K. C., Fragakis, N., Katrītis, D., Skeberis, V., and Vassilikos, V. (2014). Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. *Europace* 16, 973–979. doi:10.1093/europace/eut407
- Kowey, P. R., Dorian, P., Mitchell, L. B., Pratt, C. M., Roy, D., Schwartz, P. J., et al. (2009). Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. *Circ. Arrhythm. Electrophysiol.* 2, 652–659. doi:10.1161/circep.109.870204
- Kuck, K.-H., Brugada, J., Fürnkranz, A., Metzner, A., Ouyang, F., Chun, K. R. J., et al. (2016). Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. *N. Engl. J. Med.* 374, 2235–2245. doi:10.1056/nejmoa1602014
- Kumar, K., Nearing, B. D., Carvas, M., Nascimento, B. C. G., Acar, M., Belardinelli, L., et al. (2009). Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. *J. Cardiovasc. Electrophysiol.* 20, 796–802. doi:10.1111/j.1540-8167.2009.01437.x
- Kusunose, K., Zhang, Y., Mazgalev, T. N., Van Wagoner, D. R., Thomas, J. D., and Popović, Z. B. (2014). Impact of vagal nerve stimulation on left atrial structure and function in a canine high-rate pacing model. *Circ. Heart Fail.* 7, 320–326. doi:10.1161/circheartfailure.113.000937
- Lacerda, A. E., Kuryshv, Y. A., Yan, G.-X., Waldo, A. L., and Brown, A. M. (2010). Vanoxerine: cellular mechanism of a new antiarrhythmic. *J. Cardiovasc. Electrophysiol.* 21, 301–310. doi:10.1111/j.1540-8167.2009.01623.x
- Lafuente-Lafuente, C., Valembos, L., Bergmann, J. F., and Belmin, J. (2015). Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. *Cochrane Database Syst. Rev.*, CD005049. doi:10.1002/14651858.CD005049.pub4
- Le Heuzey, J.-Y., De Ferrari, G. M., Radzik, D., Santini, M., Zhu, J., and Davy, J.-M. (2010). A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. *J. Cardiovasc. Electrophysiol.* 21, 597–605. doi:10.1111/j.1540-8167.2010.01764.x
- Lemola, K., Chartier, D., Yeh, Y.-H., Dubuc, M., Cartier, R., Armour, A., et al. (2008). Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. *Circulation* 117, 470–477. doi:10.1161/circulationaha.107.737023
- Levitt, B., Cagin, N. A., Kleid, J., Somberg, J., and Gillis, R. (1976a). Role of the nervous system in the genesis of cardiac rhythm disorders. *Am. J. Cardiol.* 37, 1111–1113. doi:10.1016/0002-9149(76)90435-5
- Levitt, B., Cagin, N. A., Somberg, J. C., and Kleid, J. J. (1976b). Neural basis for the genesis and control of digitalis arrhythmias. *Cardiology* 61, 50–60. doi:10.1159/000169747
- Li, D., Fahren, S., Leung, T. K., and Nattel, S. (1999). Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. *Circulation* 100, 87–95. doi:10.1161/01.cir.100.1.87
- Limberg, S. H., Netter, M. F., Rolfes, C., Rinné, S., Schlichthörl, G., Zuzarte, M., et al. (2011). TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes. *Cell. Physiol. Biochem.* 28, 613–624. doi:10.1159/000335757
- Lindsay, B. D. (2011). Vernakalant: additional evidence for safety and efficacy for new onset atrial fibrillation. *J. Am. Coll. Cardiol.* 57, 322–323. doi:10.1016/j.jacc.2010.08.633
- Ling, T.-Y., Wang, X.-L., Chai, Q., Lau, T.-W., Koestler, C. M., Park, S. J., et al. (2013). Regulation of the SK3 channel by microRNA-499--potential role in atrial fibrillation. *Heart Rhythm* 10, 1001–1009. doi:10.1016/j.hrthm.2013.03.005
- Liu, L., and Nattel, S. (1997). Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. *Am. J. Physiol. Heart Circ. Physiol.* 273, H805–H816. doi:10.1152/ajpheart.1997.273.2.h805
- Liu, T., Xiong, F., Qi, X. Y., Xiao, J., Villeneuve, L., Abu-Taha, I., et al. (2020). Altered calcium handling produces reentry-promoting action potential alternans in atrial fibrillation-remodeled hearts. *JCI Insight* 5, e133754. doi:10.1172/jci.insight.133754
- Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang, F., et al. (2010). MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. *Circulation* 122, 2378–2387. doi:10.1161/circulationaha.110.958967
- Lu, Z., Scherlag, B. J., Lin, J., Niu, G., Fung, K.-M., Zhao, L., et al. (2008). Atrial fibrillation begets atrial fibrillation: autonomic mechanism for atrial electrical remodeling induced by short-term rapid atrial pacing. *Circ. Arrhythm. Electrophysiol.* 1, 184–192. doi:10.1161/circep.108.784272
- Lujan, H. L., Janbair, H., and Dicarlo, S. E. (2014). Structural remodeling of the heart and its premotor cardioinhibitory vagal neurons following T(5) spinal cord transection. *J. Appl. Physiol.* 116, 1148–1155. doi:10.1152/jappphysiol.01285.2013
- Luo, X., Pan, Z., Shan, H., Xiao, J., Sun, X., Wang, N., et al. (2013). MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. *J. Clin. Invest.* 123, 1939–1951. doi:10.1172/jci62185
- Luo, X., Yang, B., and Nattel, S. (2015). MicroRNAs and atrial fibrillation: mechanisms and translational potential. *Nat. Rev. Cardiol.* 12, 80–90. doi:10.1038/nrcardio.2014.178
- Maciag, A., Farkowski, M. M., Chwyczo, T., Beckowski, M., Syska, P., Kowalik, I., et al. (2017). Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study). *Europace* 19, 1637–1642. doi:10.1093/europace/euw384
- Marrouche, N. F., Brachmann, J., Andresen, D., Siebels, J., Boersma, L., Jordaens, L., et al. (2018). Catheter ablation for atrial fibrillation with heart failure. *N. Engl. J. Med.* 378, 417–427. doi:10.1056/nejmoa1707855
- Marrouche, N. F., Wilber, D., Hindricks, G., Jais, P., Akoum, N., Marchlinski, F., et al. (2014). Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. *JAMA* 311, 498–506. doi:10.1001/jama.2014.3
- Matsumoto, N., Khrestian, C. M., Ryu, K., Lacerda, A. E., Brown, A. M., and Waldo, A. L. (2010). Vanoxerine, a new drug for terminating atrial fibrillation and flutter. *J. Cardiovasc. Electrophysiol.* 21, 311–319. doi:10.1111/j.1540-8167.2009.01622.x
- Maykov, E. B., Yuricheva, Y. A., Mironov, N. Y., Sokolov, S. F., Golitsyn, S. P., Rosenshtraukh, L. V., et al. (2014). Efficacy of a new class III drug niferidil in cardioversion of persistent atrial fibrillation and flutter. *J. Cardiovasc. Pharmacol.* 64, 247–255. doi:10.1097/fjc.0000000000000112
- Mccord, M. C., and Taguchi, J. T. (1951). A study of the effect of procaine amide hydrochloride in supraventricular arrhythmias. *Circulation* 4, 387–393. doi:10.1161/01.cir.4.3.387
- Mcgann, C., Akoum, N., Patel, A., Kholmovski, E., Revelo, P., Damal, K., et al. (2014). Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI. *Circ. Arrhythm. Electrophysiol.* 7, 23–30. doi:10.1161/circep.113.000689
- Mcmichael, J. (1982). History of atrial fibrillation 1628-1819 Harvey - de Senac - laennec. *Heart* 48, 193–197. doi:10.1136/hrt.48.3.193
- Mcmillan, R. L., and Welfare, C. R. (1947). Chronic auricular fibrillation; its treatment with quinidine sulfate. *J. Am. Med. Assoc.* 135, 1132–1136. doi:10.1001/jama.1947.02890170010003
- Meinertz, T., Lip, G. Y. H., Lombardi, F., Sadowski, Z. P., Kalsch, B., Camez, A., et al. (2002). Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European

- Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). *Am. J. Cardiol.* 90, 1300–1306. doi:10.1016/s0002-9149(02)02867-9
- Miller, G., Weinberg, S. L., and Pick, A. (1952). The effect of procaine amide (pronestyl) in clinical auricular fibrillation and flutter. *Circulation* 6, 41–50. doi:10.1161/01.cir.6.1.41
- Miyasaka, Y., Barnes, M. E., Gersh, B. J., Cha, S. S., Bailey, K. R., Abhayaratna, W. P., et al. (2006). Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* 114, 119–125. doi:10.1161/circulationaha.105.595140
- Moreno, J., and Zamorano, J. L. (2014). The CABANA trial. *Eur. Heart J.* 35, 1908–1909
- Nakajima, T., Kurachi, Y., Ito, H., Takikawa, R., and Sugimoto, T. (1989). Anti-cholinergic effects of quinidine, disopyramide, and procainamide in isolated atrial myocytes: mediation by different molecular mechanisms. *Circ. Res.* 64, 297–303. doi:10.1161/01.res.64.2.297
- Nattel, S. (2016). How does fibrosis promote atrial fibrillation persistence: in silico findings, clinical observations, and experimental data. *Cardiovasc. Res.* 110, 295–297. doi:10.1093/cvr/cvw092
- Nattel, S., Burstein, B., and Dobrev, D. (2008). Atrial remodeling and atrial fibrillation: mechanisms and implications. *Circ. Arrhythm. Electrophysiol.* 1, 62–73. doi:10.1161/circep.107.754564
- Nattel, S., and Dobrev, D. (2012). The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. *Eur. Heart J.* 33, 1870–1877. doi:10.1093/eurheartj/ehs079
- Nerheim, P., Birger-Botkin, S., Piracha, L., and Olshansky, B. (2004). Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. *Circulation* 110, 247–252. doi:10.1161/01.cir.0000135472.28234.cc
- Ninomiya, I. (1966). Direct evidence of nonuniform distribution of vagal effects on dog atria. *Circ. Res.* 19, 576–583. doi:10.1161/01.res.19.3.576
- Nisar, M. U., Sharbaugh, M. S., Thoma, F. W., Munir, M. B., Kamran, A. S., Althouse, A. D., et al. (2016). Trends in atrial fibrillation hospitalizations from 1996 to 2010 using data from national hospital discharge survey. *Circulation* 134
- Ogawa, H., An, Y., Ikeda, S., Aono, Y., Doi, K., Ishii, M., et al. (2018). Progression from paroxysmal to sustained atrial fibrillation is associated with increased adverse events. *Stroke* 49, 2301–2308. doi:10.1161/strokeaha.118.021396
- Okumura, Y., Watanabe, I., Nakai, T., Ohkubo, K., Kofune, T., Kofune, M., et al. (2011). Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. *J. Cardiovasc. Electrophysiol.* 22, 987–993. doi:10.1111/j.1540-8167.2011.02059.x
- Olivetto, I., Cecchi, F., Casey, S. A., Dolaro, A., Traverse, J. H., and Maron, B. J. (2001). Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. *Circulation* 104, 2517–2524. doi:10.1161/hc4601.097997
- Orth, P., Hesketh, J., Mak, C., Yang, Y., Lin, S., Beach, G., et al. (2006). RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. *Cardiovasc. Res.* 70, 486–496. doi:10.1016/j.cardiores.2006.01.026
- Ott, A., Bretelet, M. M. B., De Bruyne, M. C., Van Harskamp, F., Grobbee, D. E., and Hofman, A. (1997). Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. *Stroke* 28, 316–321. doi:10.1161/01.str.28.2.316
- Packer, D. L., Mark, D. B., Robb, R. A., Monahan, K. H., Bahnson, T. D., Moretz, K., et al. (2018). Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation (CABANA) trial: study rationale and design. *Am. Heart J.* 199, 192–199. doi:10.1016/j.ahj.2018.02.015
- Patel, N. J., Deshmukh, A., Pant, S., Singh, V., Patel, N., Arora, S., et al. (2014). Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. *Circulation* 129, 2371–2379. doi:10.1161/circulationaha.114.008201
- Patten, M., Maas, R., Bauer, P., Luderitz, B., Sonntag, F., Dlugniewski, M., et al. (2004). Suppression of paroxysmal atrial tachyarrhythmias—results of the SOPAT trial. *Eur. Heart J.* 25, 1395–1404. doi:10.1016/j.ehj.2004.06.014
- Peigh, G., Kaplan, R. M., Bavishi, A., Diaz, C. L., Baman, J. R., Matiasz, R., et al. (2020). A novel risk model for very late return of atrial fibrillation beyond 1 year after cryoballoon ablation: the SCALE-CryoAF score. *J. Intervent. Card. Electrophysiol.* 58 (2), 209–217. doi:10.1007/s10840-019-00588-x
- Piccini, J. P., Pritchett, E. L. C., Davison, B. A., Cotter, G., Wiener, L. E., Koch, G., et al. (2016). Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: restore SR. *Heart Rhythm* 13, 1777–1783. doi:10.1016/j.hrthm.2016.04.012
- Pokushalov, E., Kozlov, B., Romanov, A., Strelnikov, A., Bayramova, S., Sergeevichev, D., et al. (2015). Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: one-year follow-up of a randomized pilot study. *Circ. Arrhythm. Electrophysiol.* 8, 1334–1341. doi:10.1161/circep.115.003199
- Pratt, C. M., Roy, D., Torp-Pedersen, C., Wyse, D. G., Toft, E., Juul-Moller, S., et al. (2010). Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. *Am. J. Cardiol.* 106, 1277–1283. doi:10.1016/j.amjcard.2010.06.054
- Qi, X.-Y., Diness, J. G., Brundel, B. J. J. M., Zhou, X.-B., Naud, P., Wu, C.-T., et al. (2014). Role of small-conductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog. *Circulation* 129, 430–440. doi:10.1161/circulationaha.113.003019
- Qu, Y.-C., Du, Y.-M., Wu, S.-L., Chen, Q.-X., Wu, H.-L., and Zhou, S.-F. (2009). Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. *Scand. Cardiovasc. J.* 43, 292–297. doi:10.1080/14017430802651803
- Reiffel, J. A., Camm, A. J., Belardinelli, L., Zeng, D., Karwowska-Prokopczuk, E., Olmsted, A., et al. (2015). The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. *Circ. Arrhythm. Electrophysiol.* 8, 1048–1056. doi:10.1161/circep.115.002856
- Rinné, S., Kiper, A. K., Schlichthörl, G., Dittmann, S., Netter, M. F., Limberg, S. H., et al. (2015). TASK-1 and TASK-3 may form heterodimers in human atrial cardiomyocytes. *J. Mol. Cell. Cardiol.* 81, 71–80. doi:10.1016/j.yjmcc.2015.01.017
- Romanov, A., Pokushalov, E., Ponomarev, D., Bayramova, S., Shabanov, V., Losik, D., et al. (2019). Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery: three-year follow-up of a randomized study. *Heart Rhythm* 16, 172–177. doi:10.1016/j.hrthm.2018.08.019
- Rossi, P., Ricci, A., De Paulis, R., Papi, E., Pavaci, H., Porcelli, D., et al. (2012). Epicardial ganglionated plexus stimulation decreases postoperative inflammatory response in humans. *Heart Rhythm* 9, 943–950. doi:10.1016/j.hrthm.2012.01.025
- Roy, D., Pratt, C. M., Torp-Pedersen, C., Wyse, D. G., Toft, E., Juul-Moller, S., et al. (2008). Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. *Circulation* 117, 1518–1525. doi:10.1161/circulationaha.107.723866
- Roy, D., Talajic, M., Dorian, P., Connolly, S., Eisenberg, M. J., Green, M., et al. (2000). Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. *N. Engl. J. Med.* 342, 913–920. doi:10.1056/nejm200003303421302
- Rozen, G., Hosseini, S. M., Kaadan, M. I., Biton, Y., Heist, E. K., Vangel, M., et al. (2018). Emergency department visits for atrial fibrillation in the United States: trends in admission rates and economic burden from 2007 to 2014. *J. Am. Heart Assoc.* 7, e009024. doi:10.1161/jaha.118.009024
- Savelieva, I., Kakouros, N., Kourliouros, A., and Camm, A. J. (2011a). Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. *Europace* 13, 308–328. doi:10.1093/europace/eur002
- Savelieva, I., Kakouros, N., Kourliouros, A., and Camm, A. J. (2011b). Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. *Europace* 13, 610–625. doi:10.1093/europace/eur023
- Schmidt, C., Wiedmann, F., Beyersdorf, C., Zhao, Z., El-Battrawy, I., Lan, H., et al. (2019). Genetic ablation of TASK-1 (tandem of P domains in a weak inward rectifying K(+) channel-related acid-sensitive K(+) channel-1) (K(2P)3.1) K(+) channels suppresses atrial fibrillation and prevents electrical remodeling. *Circ. Arrhythmia Electrophysiol.* 12, e007465. doi:10.1161/circep.119.007465
- Schmidt, C., Wiedmann, F., Voigt, N., Zhou, X.-B., Heijman, J., Lang, S., et al. (2015). Upregulation of K(2P)3.1 K+ current causes action potential shortening

- in patients with chronic atrial fibrillation. *Circulation* 132, 82–92. doi:10.1161/circulationaha.114.012657
- Schmidt, C., Wiedmann, F., Zhou, X. B., Heijman, J., Voigt, N., Ratte, A., et al. (2017). Inverse remodelling of K2P3.1 K⁺ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. *Eur. Heart J.* 38, 1764–1774. doi:10.1093/eurheartj/ehx493.p5835
- Schnabel, R. B., Sullivan, L. M., Levy, D., Pencina, M. J., Massaro, J. M., D'agostino, R. B., et al. (2009). Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. *Lancet* 373, 739–745. doi:10.1016/s0140-6736(09)60443-8
- Schnabel, R. B., Yin, X., Gona, P., Larson, M. G., Beiser, A. S., McManus, D. D., et al. (2015). 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet* 386, 154–162. doi:10.1016/s0140-6736(14)61774-8
- Sharifov, O. F., Fedorov, V. V., Beloshapko, G. G., Glukhov, A. V., Yushmanova, A. V., and Rosenshtraukh, L. V. (2004). Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. *J. Am. Coll. Cardiol.* 43, 483–490. doi:10.1016/j.jacc.2003.09.030
- Shelton, R. J., Clark, A. L., Goode, K., Rigby, A. S., Houghton, T., Kaye, G. C., et al. (2009). A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). *Heart* 95, 924–930. doi:10.1136/hrt.2008.158931
- Shen, M. J., Shinohara, T., Park, H.-W., Frick, K., Ice, D. S., Choi, E.-K., et al. (2011). Continuous low-level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines. *Circulation* 123, 2204–2212. doi:10.1161/circulationaha.111.018028
- Shen, N.-N., Zhang, C., Li, Z., Kong, L.-C., Wang, X.-H., Gu, Z.-C., et al. (2020). MicroRNA expression signatures of atrial fibrillation: the critical systematic review and bioinformatics analysis. *Exp. Biol. Med.* 245, 42–53. doi:10.1177/1535370219890303
- Sheng, X., Scherlag, B. J., Yu, L., Li, S., Ali, R., Zhang, Y., et al. (2011). Prevention and reversal of atrial fibrillation inducibility and autonomic remodeling by low-level vagosympathetic nerve stimulation. *J. Am. Coll. Cardiol.* 57, 563–571. doi:10.1016/j.jacc.2010.09.034
- Shunmugam, S. R., Sugihara, C., Freemantle, N., Round, P., Furniss, S., and Sulke, N. (2018). A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy. *J. Intervent. Card Electrophysiol.* 51, 191–197. doi:10.1007/s10840-018-0318-2
- Sieweke, J. T., Pfeffer, T. J., Biber, S., Chatterjee, S., Weissenborn, K., Grosse, G. M., et al. (2020). miR-21 and NT-proBNP correlate with echocardiographic parameters of atrial dysfunction and predict atrial fibrillation. *J. Clin. Med.* 9, 1118. doi:10.3390/jcm9041118
- Silverman, M. E. (1994). From rebellious palpitations to the discovery of auricular fibrillation: contributions of Mackenzie, Lewis and Einthoven. *Am. J. Cardiol.* 73, 384–389. doi:10.1016/0002-9149(94)90013-2
- Simon, A., Niederdoeckl, J., Skyllouriotis, E., Schuetz, N., Herkner, H., Weiser, C., et al. (2017). Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. *Europace* 19, 233–240. doi:10.1093/europace/euw052
- Simopoulos, V., Hevas, A., Hatziefthimiou, A., Dipla, K., Skoularigis, I., Tsilimingas, N., et al. (2018). Amiodarone plus ranolazine for conversion of post-cardiac surgery atrial fibrillation: enhanced effectiveness in reduced versus preserved ejection fraction patients. *Cardiovasc. Drugs Ther.* 32, 559–565. doi:10.1007/s10557-018-6832-8
- Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., et al. (2005). Amiodarone versus sotalol for atrial fibrillation. *N. Engl. J. Med.* 352, 1861–1872. doi:10.1056/nejmoa041705
- Singh, S., Zoble, R. G., Yellen, L., Brodsky, M. A., Feld, G. K., Berk, M., et al. (2000). Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. *Circulation* 102, 2385–2390. doi:10.1161/01.cir.102.19.2385
- Soeki, T., Matsuura, T., Bando, S., Tobiume, T., Uematsu, E., Ise, T., et al. (2016). Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation. *J. Cardiol.* 68, 472–477. doi:10.1016/j.jcc.2015.12.007
- Sonmez, O., Ertem, F. U., Vatankulu, M. A., Erdogan, E., Tasal, A., Kucukbuzcu, S., et al. (2014). Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation. *Med. Sci. Monit.* 20, 463–470. doi:10.12659/MSM.890635
- Staerk, L., Wang, B., Preis, S. R., Larson, M. G., Lubitz, S. A., Ellinor, P. T., et al. (2018). Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. *BMJ* 361, k1453. doi:10.1136/bmj.k1453
- Stavrakis, S., Humphrey, M. B., Scherlag, B. J., Hu, Y., Jackman, W. M., Nakagawa, H., et al. (2015). Low-level transcatheter electrical vagus nerve stimulation suppresses atrial fibrillation. *J. Am. Coll. Cardiol.* 65, 867–875. doi:10.1016/j.jacc.2014.12.026
- Stavrakis, S., Humphrey, M. B., Scherlag, B. J., Iftikhar, O., Parwani, P., Abbas, M., et al. (2017). Low-level vagus nerve stimulation suppresses post-operative atrial fibrillation and inflammation: a randomized study. *JACC Clinical Electrophysiol.* 3, 929–938. doi:10.1016/j.jacep.2017.02.019
- Stavrakis, S., Stoner, J. A., Humphrey, M. B., Morris, L., Filiberti, A., Reynolds, J. C., et al. (2020). TREAT AF (transcatheter electrical vagus nerve stimulation to suppress atrial fibrillation): a randomized clinical trial. *JACC Clinical Electrophysiol.* 6, 282–291. doi:10.1016/j.jacep.2019.11.008
- Stewart, S., Hart, C. L., Hole, D. J., and McMurray, J. J. V. (2002). A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am. J. Med.* 113, 359–364. doi:10.1016/s0002-9343(02)01236-6
- Stiell, I. G., Roos, J. S., Kavanagh, K. M., and Dickinson, G. (2010). A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. *Am. Heart J.* 159, 1095–1101. doi:10.1016/j.ahj.2010.02.035
- Takei, M., Tsuboi, M., Usui, T., Hanaoka, T., Kurogouchi, F., Aruga, M., et al. (2001). Vagal stimulation prior to atrial rapid pacing protects the atrium from electrical remodeling in anesthetized dogs. *Jpn. Circ. J.* 65, 1077–1081. doi:10.1253/cj.65.1077
- Teh, A. W., Kistler, P. M., Lee, G., Medi, C., Heck, P. M., Spence, S. J., et al. (2012). Electroanatomic remodeling of the left atrium in paroxysmal and persistent atrial fibrillation patients without structural heart disease. *J. Cardiovasc. Electrophysiol.* 23, 232–238. doi:10.1111/j.1540-8167.2011.02178.x
- Thacker, E. L., Mcknight, B., Psaty, B. M., Longstreth, W. T., Jr., Dublin, S., Jensen, P. N., et al. (2013). Association of body mass index, diabetes, hypertension, and blood pressure levels with risk of permanent atrial fibrillation. *J. Gen. Intern. Med.* 28, 247–253. doi:10.1007/s11606-012-2220-4
- Toale, C., Fitzmaurice, G. J., Eaton, D., Lyne, J., and Redmond, K. C. (2019). Outcomes of left atrial appendage occlusion using the AtriClip device: a systematic review. *Interact. Cardiovasc. Thorac. Surg.* 29, 655–662. doi:10.1093/icvts/ivz156
- Van Wagoner, D. R., Pond, A. L., Lamorgese, M., Rossie, S. S., Mccarthy, P. M., and Nerbonne, J. M. (1999). Atrial L-type Ca²⁺ currents and human atrial fibrillation. *Circ. Res.* 85, 428–436. doi:10.1161/01.res.85.5.428
- Vaughan Williams, E. M. (1984). A classification of antiarrhythmic actions reassessed after a decade of new drugs. *J. Clin. Pharmacol.* 24, 129–147. doi:10.1002/j.1552-4604.1984.tb01822.x
- Wang, X., Zhao, Q., Huang, H., Tang, Y., Xiao, J., Dai, Z., et al. (2013). Effect of renal sympathetic denervation on atrial substrate remodeling in ambulatory canines with prolonged atrial pacing. *PLoS One* 8, e64611. doi:10.1371/journal.pone.0064611
- Warrington, S. J., and Hamer, J. (1980). Some cardiovascular problems with disopyramide. *Postgrad. Med.* 56, 229–233. doi:10.1136/pgmj.56.654.229
- Watanabe, A. M. (1985). Digitalis and the autonomic nervous system. *J. Am. Coll. Cardiol.* 5, 35a–42a. doi:10.1016/s0735-1097(85)80461-7
- Wegria, R. (1947). Correlation between the effect of quinidine sulfate on the rate of the circus movement in auricular fibrillation and its concentration in the blood plasma. *J. Clin. Invest.* 26, 1200
- Weiss, J. N., Qu, Z., and Shivkumar, K. (2016). Ablating atrial fibrillation: a translational science perspective for clinicians. *Heart Rhythm* 13, 1868–1877. doi:10.1016/j.hrthm.2016.05.026
- Wettwer, E., Christ, T., Endig, S., Rozmarits, N., Matschke, K., Lynch, J. J., et al. (2013). The new antiarrhythmic drug vernakalant: *ex vivo* study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. *Cardiovasc. Res.* 98, 145–154. doi:10.1093/cvr/cvt006

- White, C. M., and Nguyen, E. (2017). Novel use of ranolazine as an antiarrhythmic agent in atrial fibrillation. *Ann. Pharmacother.* 51, 245–252. doi:10.1177/1060028016673073
- Wiedmann, F., Beyersdorf, C., Zhou, X., Büscher, A., Kraft, M., Nietfeld, J., et al. (2020). Pharmacologic TWIK-related acid-sensitive K⁺ channel (TASK-1) potassium channel inhibitor A293 facilitates acute cardioversion of paroxysmal atrial fibrillation in a porcine large animal model. *J. Am. Heart Assoc.* 9, e015751. doi:10.1161/jaha.119.015751
- Wijffels, M. C. E. F., Kirchhof, C. J. H. J., Dorland, R., and Allessie, M. A. (1995). Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation* 92, 1954–1968. doi:10.1161/01.cir.92.7.1954
- Withering, W. (1785). *An account of the foxglove and some of its medical uses: with practical remarks on dropsy and other diseases*. Birmingham.
- Wolf, P. A., Abbott, R. D., and Kannel, W. B. (1991). Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 22, 983–988. doi:10.1161/01.str.22.8.983
- Wray, S., Eisner, D. A., and Allen, D. G. (1985). Two hundred years of the foxglove. *Med. Hist.* 29, 132–150. doi:10.1017/s0025727300070551
- Wybraniec, M. T., Wróbel, W., Wilkosz, K., Wrona, K., Bula, K., and Mizia-Steć, K. (2018). Pharmacological cardioversion with antazoline in atrial fibrillation: the results of the CANT study. *J. Am. Heart Assoc.* 7, e010153. doi:10.1161/jaha.118.010153
- Wyse, D. G., Waldo, A. L., Dimarco, J. P., Domanski, M. J., Rosenberg, Y., Schron, E. B., et al. (2002). A comparison of rate control and rhythm control in patients with atrial fibrillation. *N. Engl. J. Med.* 347, 1825–1833. doi:10.1056/nejmoa021328
- Yao, C., Veleva, T., Scott, L., Jr., Cao, S., Li, L., Chen, G., et al. (2018). Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. *Circulation* 138, 2227–2242. doi:10.1161/circulationaha.118.035202
- Youssef, I., Kamran, H., Yacoub, M., Patel, N., Goulbourne, C., Kumar, S., et al. (2018). Obstructive sleep apnea as a risk factor for atrial fibrillation: a meta-analysis. *J. Sleep Disord. Ther.* 7, 282. doi:10.4172/2167-0277.1000282
- Yu, L., Scherlag, B. J., Li, S., Sheng, X., Lu, Z., Nakagawa, H., et al. (2011). Low-level vagosympathetic nerve stimulation inhibits atrial fibrillation inducibility: direct evidence by neural recordings from intrinsic cardiac ganglia. *J. Cardiovasc. Electrophysiol.* 22, 455–463. doi:10.1111/j.1540-8167.2010.01908.x
- Yue, L., Feng, J., Gaspo, R., Li, G.-R., Wang, Z., and Nattel, S. (1997). Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. *Circ. Res.* 81, 512–525. doi:10.1161/01.res.81.4.512
- Zareba, K. M. (2006). Dronedarone: a new antiarrhythmic agent. *Drugs Today* 42, 75–86. doi:10.1358/dot.2006.42.2.925346
- Zhang, Y., Ilsa, I., Sabbah, H. N., Ben David, T., and Mazgalev, T. N. (2009a). Relationship between right cervical vagus nerve stimulation and atrial fibrillation inducibility: therapeutic intensities do not increase arrhythmogenesis. *Heart Rhythm* 6, 244–250. doi:10.1016/j.hrthm.2008.10.043
- Zhang, Y., Popović, Z. B., Bibevski, S., Fakhry, I., Sica, D. A., Van Wagoner, D. R., et al. (2009b). Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. *Circ. Heart Fail.* 2, 692–699. doi:10.1161/circheartfailure.109.873968
- Zhang, Y., Scherlag, B. J., Lu, Z., Niu, G.-D., Yamanashi, W. S., Hogan, C., et al. (2009c). Comparison of atrial fibrillation inducibility by electrical stimulation of either the extrinsic or the intrinsic autonomic nervous systems. *J. Intervent. Card Electrophysiol.* 24, 5–10. doi:10.1007/s10840-008-9297-z

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Geng, Lin and Nguyen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.